hydrazine has been researched along with Autoimmune Thrombocytopenia in 299 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 34 (11.37) | 29.6817 |
| 2010's | 185 (61.87) | 24.3611 |
| 2020's | 80 (26.76) | 2.80 |
| Authors | Studies |
|---|---|
| Bussel, JB; Khelif, A; Maier, J; Meyer, O; Saleh, MN; Stankovic, M; Wong, RSM | 1 |
| Ferdjallah, A; Hermann, E | 1 |
| Cuker, A; Geevarghese, L; Lal, LS; Landsteiner, A; Le, L; Nandal, S; Patwardhan, P | 1 |
| Baldacci, E; Botta, C; Caracciolo, D; Ferretti, A; Gentile, M; Lucia, E; Martino, E; Mendicino, F; Morelli, M; Muto, B; Santoro, C; Vigna, E | 1 |
| Lebioda, A; Meyer, O; Richter, H; Schill, M | 1 |
| Chen, Z; Cheng, X; Fu, L; Gu, H; Ma, J; Wang, X; Wu, R; Zhao, L | 1 |
| Dong, H; Hu, H; Li, Y; Liu, Q; Liu, W; Shen, Y; Wu, D; Ye, B; Zhao, Y; Zhou, Y | 1 |
| Cracowski, JL; Imbert, B; Khouri, C; Park, S; Perez, J | 1 |
| Ambrosiani, L; Feltri, M; Gardellini, A; Guidotti, F; Maino, E; Turrini, M; Zancanella, M | 1 |
| Aroichane, M; Audia, S; Beyne-Rauzy, O; Chèze, S; Comont, T; Ebbo, M; Germain, J; Godeau, B; Lafaurie, M; Lapeyre-Mestre, M; Leclerc-Teffahi, S; Mahévas, M; Michel, M; Moulis, G; Rueter, M; Sommet, A; Viallard, JF | 1 |
| Arnold, DM; Blostein, M; Carruthers, J; Cook, RJ; Heddle, NM; Hsia, C; Jamula, E; Kassis, J; Kaur, MN; Larratt, L; Li, N; Lin, Y; Liu, Y; Sholzberg, M; Tinmouth, A; Xie, F | 1 |
| Becattini, C; Maraziti, G | 1 |
| Dichtwald, S; Ifrach, N; Meyer, A | 1 |
| Autore, F; Chiusolo, P; Colangelo, M; Minnella, G; Rossi, E; Sica, S; Sora', F | 1 |
| Argenziano, M; Catanoso, M; Ceglie, G; Di Leva, C; Di Paola, A; Locatelli, F; Palumbo, G; Perrotta, S; Rossi, F; Tortora, C | 1 |
| Al-Samkari, H; Ayad, N; Grace, RF | 1 |
| Bao, X; Ji, C; Yuan, C; Zhang, N | 1 |
| Fan, J; He, J; Hu, S; Zhou, H | 1 |
| Will, B | 1 |
| Bang, SM; Kim, JH; Kim, JW; Kim, SA; Kim, SH; Kim, YJ; Lee, JH; Lee, JO; Lee, JS; Lee, JY; Lee, KW; Suh, KJ | 1 |
| Argilés, B; Astigarraga, I; Berrueco, R; Cervera, Á; Dapena, JL; Dasí, MÁ; Monteagudo, E; Sastre, A; Sebastián, E; Solsona, M | 1 |
| Kapur, R | 1 |
| Barcellini, W; Bortolotti, M; Cantoni, S; Capecchi, M; Cecchi, N; Chen, F; Fattizzo, B; Frederiksen, H; Giordano, G; Glenthøj, A; Gonzaléz-Lopez, TJ; Mingot-Castellano, ME; Napolitano, M; Patriarca, A | 1 |
| Carlyle, M; Cuker, A; Elliott, C; Haenig, J; Lal, L; Martin, C; Roy, A; Viana, R | 1 |
| Angchaisuksiri, P; Elghandour, A; Frueh, JA; Goldbrunner, M; Ingles, S; Jang, JH; Mattar, M; Ozcan, M; Rahman, M; Tarkun, P; Wei, X; Wong, RSM; Yang, R; Yassin, MA; Yavaşoğlu, İ; Yoon, SS | 1 |
| Bolster, L; Goodyear, MD; Patterson, JM; Podstawka, J; Rydz, N; Sun, HL; Wall, E | 1 |
| Li, F; Luo, S; Xu, Y; Yang, F; Zhang, X; Zong, H | 1 |
| Alrajhi, Z; Jackson, M; Kirby-Allen, M; Klaassen, RJ; Livingston, J; McGuire, C; Newhook, D | 1 |
| Al-Samkari, H | 1 |
| Cai, X; Chang, Y; Fu, H; Huang, X; Jiang, Q; Lu, J; Zhang, X; Zhao, X | 1 |
| Feng, CX; Geng, QC; Lin, X; Liu, Y; Su, J; Zhang, HX | 1 |
| Feng, X; Hua, B; Li, W; Ma, L; Wang, D; Wang, F; Wang, H; Zhu, Y | 1 |
| Fijnheer, R; Huisman, A; Koene, HR; Poolen, GC; Schutgens, REG; Thielen, N; Urbanus, RT; van Bladel, ER; van Dijk, WEM; van Galen, KPM | 1 |
| Barlassina, A; Cooper, N; González-López, TJ; Zaja, F | 1 |
| Carmi, O; Garra, W; Kivity, S; Levy, Y | 1 |
| Bátorová, A; Bodó, I; Červinek, L; Ionita, I; Lissitchkov, T; Melikyan, A; Podolak-Dawidziak, M; Pulanić, D | 1 |
| Audia, S; Azzaoui, I; Belmondo, T; Bonnotte, B; Boutin, E; Canoui-Poitrine, F; Chappert, P; Cheze, S; Comont, T; Crickx, E; Fain, O; Galicier, L; Gerfaud-Valentin, M; Gobert, D; Godeau, B; Guillet, S; Hamidou, M; Hue, S; Lambotte, O; Languille, L; Le Gallou, T; Lefrere, F; Lega, JC; Limal, N; Luka, M; Mahévas, M; Malphettes, M; Marolleau, JP; Martis, N; Menager, M; Michel, M; Morin, AS; Moulis, G; Noel, N; Perlat, A; Puyade, M; Rivière, E; Robbins, A; Roy-Peaud, F; Terriou, L; Viallard, JF; Zarrour, A | 1 |
| Li, T; Liu, J; Liu, Q; Pu, T; Zhang, A | 1 |
| Chen, Z; Cheng, X; Dong, S; Hu, Y; Liu, Y; Ma, J; Meng, J; Wang, L; Wang, Z; Wu, R | 1 |
| Borchiellini, A; Dufour, C; Farruggia, P; Giona, F; Giordano, P; Ladogana, S; Palumbo, G; Perrotta, S; Pession, A; Ramenghi, U; Russo, G; Spinelli, M; Zecca, M | 1 |
| Bussel, JB; Jamieson, BD; Lee, EJ; Tarantino, MD | 1 |
| Bastiaanse, M; Daykin-Pont, O; Eriksson, D; Geldman, E; Gerard Jansen, AJ; McDonald, V; Morgan, M; Newland, A; Prince, S; Wilson, K; Zwaginga, JJ | 1 |
| Nikuze, L; Pang, C; Wei, H; Wu, X | 1 |
| Attia, J; Ingsathit, A; McEvoy, M; Puavilai, T; Rattanasiri, S; Thadanipon, K; Thakkinstian, A | 1 |
| Borchiellini, A; Carli, G; d'Amore, ESG; Lucchini, E; Merli, M; Motta, G; Passamonti, F; Quaresimini, G; Rambaldi, A; Rodeghiero, F; Romano, A; Ruggeri, M; Santi, RM; Valeri, F; Visco, C; Volpetti, S | 1 |
| Alvarez-Roman, MT; Bermejo, N; Bolaños, E; Campos-Alvarez, RM; Carreño-Tarragona, G; Casado-Montero, LF; de Andrés, A; González-López, TJ; González-Porras, JR; Jarque, I; Lopez-Fernandez, MF; Lozano, ML; Mingot-Castellano, ME; Novelli, S; Orna-Montero, E; Orts, MI; Perera, MM; Revilla, N; Rodríguez-López, MA; Valcarcel, D; Vicente, V | 1 |
| Hayashi, K; Honma, M; Iinuma, S; Ishida-Yamamoto, A; Kanno, K; Kinouchi, M; Nagasawa, Y; Obata, M; Sasaki, K; Sugawara, M | 1 |
| Bernat, S; Bolaños, E; Caparrós, I; de Cabo, E; Fernández-Fuertes, F; Fernández-Miñano, C; Fernández-Rodríguez, A; García-Frade, LJ; Gómez-Nuñez, M; González-López, TJ; Hernández-Rivas, JA; Jarque, I; López-Ansoar, E; Martínez Badas, MP; Martínez-Robles, V; Olivera, P; Pascual, C; Peñarrubia, MJ; Perdomo, G; Pérez-Rus, G; Sánchez-González, B; Soto, I; Yera Cobo, M | 1 |
| Chen, N; Hamzeh, I; Kamran, H; Mims, M; Sudhakar, D | 1 |
| Baricault, B; Cassagne, M; Lafaurie, M; Lapeyre-Mestre, M; Moulis, G; Sailler, L; Soler, V; Sommet, A | 1 |
| Allepuz, A; Bhor, M; Forsythe, A; Kwon, CS; Pham, T; Roy, AN; Said, Q; Schneider, J; Socorro O Portella, MD | 1 |
| Akbayram, S; Albayrak, M; Bör, Ö; Çakmaklı, HF; Celkan, T; Çınar Özel, S; Erduran, E; Gürlek Gökçebay, D; Karakaş, Z; Karaman, S; Koca Yozgat, A; Koçak, Ü; Leblebisatan, G; Malbora, B; Ören, H; Oymak, Y; Özbek, NY; Özdemir, GN; Şaşmaz, İ; Söker, M; Tokgöz, H; Ünal, Ş; Ünüvar, A; Yaralı, N; Yılmaz, Ş; Zengin, E | 1 |
| Dolph, M; Forsythe, A; Roy, AN; Said, Q; Tremblay, G | 1 |
| Bain, BJ; Cooper, N; Holyome, A; Qureshi, A | 1 |
| Corallo, PC; Faienza, MF; Giordano, P; Lassandro, G; Palladino, V; Palmieri, VV; Vecchio, GCD | 1 |
| Ambrosiani, L; Feltri, M; Gardellini, A; Guidotti, F; Saccà, V; Turrini, M; Zancanella, M | 1 |
| Ebbo, M; Godeau, B; Rivière, E | 1 |
| Alkindi, S; Bussel, JB; Cheze, S; Ebbo, M; Ghanima, W; Godeau, B; Gonzalez-Lopez, TJ; Michel, M; Ruggeri, M; Terriou, L; Tvedt, THA | 1 |
| Bocchia, M; Cencini, E; Ciofini, S; Defina, M; Sammartano, V; Santoni, A | 1 |
| Bussel, JB; Kuter, D | 1 |
| Aguilar-Calderón, P; Gómez-Almaguer, D; Jaime-Pérez, JC; Jiménez-Castillo, RA; Ramos-Dávila, EM; Salazar-Cavazos, L | 1 |
| Anguita, E; González-Porras, JR; Parrondo García, FJ | 1 |
| Chiba, S; Doki, K; Homma, M; Obara, N; Sakata-Yanagimoto, M; Yanagimachi, N | 1 |
| Chen, M; Fang, JP; Li, XY; Lin, SF; Xu, LH; Zhou, CX | 1 |
| Argenziano, M; Di Paola, A; Merli, P; Palumbo, G; Perrotta, S; Roberti, D; Rossi, F; Santoro, C; Strocchio, L; Tortora, C | 1 |
| Aladjidi, N; Barlogis, V; Benadiba, J; Blouin, P; Ducassou, S; Fahd, M; Fernandes, H; Jeziorski, E; Leblanc, T; Leverger, G; Michel, M; Nolla, M; Pasquet, M; Pondarre, C | 1 |
| Auteri, G; Barcellini, W; Boggio, E; Carli, G; Carpenedo, M; Celli, M; Consoli, U; Crea, E; Dianzani, U; Fanin, R; Giardini, I; Gigliotti, CL; Lucchini, E; Palandri, F; Paoloni, F; Patriarca, A; Rodeghiero, F; Rossi, E; Santoro, C; Valeri, F; Vianelli, N; Vignetti, M; Volpetti, S; Zaja, F | 1 |
| Chen, Z; Fu, L; Gu, H; Ma, J; Wei, Y; Wu, R | 1 |
| Chen, S; Dai, M; Fu, Q; Wang, J | 1 |
| Maeda, Y; Tamai, Y; Yamamoto, D | 1 |
| Bradbury, C; Cooper, N; Grainger, J; Hill, QA; Provan, D; Ramscar, N; Roy, A; Thachil, J; Westwood, JP | 1 |
| Ghosh, SA; Maw, KZ; Patrick, J | 1 |
| Majewska, R; Tomiyama, Y; Wong, TF | 1 |
| Auteri, G; Baldacci, E; Barcellini, W; Bartoletti, D; Borchiellini, A; Cantoni, S; Caocci, G; Carli, G; Carpenedo, M; Carrai, V; Cavo, M; Chiurazzi, F; Consoli, U; De Stefano, V; Ferretti, A; Giuffrida, G; Lucchini, E; Mazzucconi, MG; Nicolosi, D; Oliva, EN; Palandri, F; Patriarca, A; Rivolti, E; Rodeghiero, F; Rossi, E; Ruggeri, M; Sutto, E; Vianelli, N; Zaja, F | 1 |
| Ceglie, G; Clemente, V; De Gennaro, F; Di Mauro, M; Nocentini, G; Palumbo, G | 1 |
| Baş, V; Baysal, M; Demir, AM; Kırkızlar, HO; Ümit, E | 1 |
| Bilgir, O; Doğan, EE; Eren, R; Namdaroğlu, S; Nizam, N; Turan Erkek, E; Uğur, MC | 1 |
| Álvarez-Roman, MT; Butta, N; Coma, M; González-Porras, JR; Gutiérrez, L; Lozano, ML; Segú-Vergés, C; Valcárcel, D | 1 |
| Miao, W; Zhang, P | 1 |
| Bennett, CM; Despotovic, JM; Grace, RF; Klaassen, RJ; London, WB; Ma, C; Neufeld, EJ; Neunert, C; Shimano, KA | 1 |
| Grainger, JD; Thind, S | 1 |
| Alonso, A; Alonso, R; Alvarez-Román, MT; Arrieta-Cerdán, E; Bastida, JM; Bernat, S; Bolaños, E; Caparrós, I; Entrena, L; Fernández-Fuentes, F; García-Frade, J; Gómez-Nuñez, M; González-López, TJ; González-Porras, JR; Hernández-Rivas, JA; Lopez-Ansoar, E; Martínez-Badas, MP; Martínez-Robles, V; Olivera, P; Pascual, C; Pérez-Rus, G; Sánchez-González, B; Soto, I; Tenorio, M; Yera Cobo, M | 1 |
| Aguilar, C; Alvarez-Román, MT; Arrieta-Cerdán, E; Bárez, A; Bernat, S; de Cabo, E; Fernández-Fuertes, F; Fernández-Rodríguez, A; García-Frade, LJ; González-López, TJ; González-Porras, JR; Hernández-Rivas, JA; Martínez-Robles, V; Olivera, P; Pascual, C; Peñarrubia, MJ; Pérez-Rus, G; Sánchez-González, B | 1 |
| Fernández-Fuertes, F; Hernández, MT; Lakhwani, S; Perera, M; Raya, JM; Ríos de Paz, MA; Torres, M | 1 |
| Ai, Y; Li, Y; Liang, Y; Xie, J; Zhang, J; Zheng, W | 1 |
| Babinchak, T; Bilir, SP; Donga, PZ; Little, G; Munakata, J | 1 |
| Gao, Y; Gong, M; Kong, X; Ma, Y; Zhang, C | 1 |
| Bagai, A; Hashi, A; Sholzberg, M; Taher, A; Teichman, J | 1 |
| Kiss, C; Kovács, G | 1 |
| Agnelli Giacchello, J; Boccadoro, M; Borchiellini, A; Valeri, F | 1 |
| Cantú-Rodríguez, OG; Colunga-Pedraza, PR; Gómez-Almaguer, D; Gómez-De León, A; Gutiérrez-Aguirre, CH; Jaime-Pérez, JC | 1 |
| Kanno, M; Meguro, T; Mitsui, T; Onoda, T; Sato, H | 1 |
| Berdejo, J; Cequier, A; Cubero-Gallego, H; Gomez-Hospital, JA; Gomez-Lara, J; Romaguera, R; Teruel, L | 1 |
| Despotovic, J; Kim, TO; Lambert, MP | 1 |
| Brunet, E; Calvet, X; Garcia-Iglesias, P; Martínez de Sola, M | 1 |
| Aslanis, V; Li, X; Ouatas, T; Sallas, W; Wire, MB; Zhang, J | 1 |
| Carlson, A; Lusa, A | 1 |
| Caparrós, IS; Casaus García, A; Díaz-Canales, D; Fernández, F; González-Silva, M; Jimenez-Bárcenas, R; Mingot-Castellano, ME; Nieto-Hernandez, MM; Perera-Alvarez, MDM; Rodríguez-Fernandez, MJ; Yera-Cobo, M | 1 |
| Bhor, M; Briggs, A; Dolph, M; Forsythe, A; Hearnden, J; Kwon, CS; Roy, A; Tremblay, G | 1 |
| Aboud, N; Depré, F; Mayer, B; Salama, A | 2 |
| Ai, Y; He, R; Li, X; Li, Y; Liang, Y; Xie, J; Zhang, J; Zheng, W | 1 |
| Lai, CY; Pettit, T | 1 |
| Balduini, CL; Pecci, A; Rodeghiero, F | 1 |
| Atsumi, T; Kanda, M | 1 |
| Al-Samkari, H; Kuter, DJ | 3 |
| Areia, ALFA; Carda, J; Ferreira, IJMCF; Moura, JPAS; Ribeiro, L; Sousa, F; Vasco, EM | 1 |
| Campioni, M; Cetin, K; Chandler, D; Eisen, M; Fust, K; Li, X; Lin, J; Parthan, A; Sharma, A; Wang, X; Zhang, X; Zur, R | 1 |
| Bezold, C; Bylsma, LC; Callaghan, F; Cetin, K; Fryzek, JP; Mehta, B; Wasser, JS | 1 |
| Cooper, N; Fanin, R; Lucchini, E; Zaja, F | 1 |
| Blanchette, VS; Bussel, JB; Grainger, JD; Grotzinger, KM; Roy, A | 1 |
| Neunert, CE | 1 |
| Arshanskaya, EG; Chernikov, MV; Pankrashkina, MM; Ptushkin, VV; Tkachenko, NE; Vinogradova, OY | 1 |
| Li, A; Liu, X; Wang, JY; Wang, L; Wang, X | 1 |
| Auteri, G; Barcellini, W; Cantoni, S; Carpenedo, M; Consonni, D; D'Adda, M; Fattizzo, B; Gramegna, D; Napolitano, M; Pasquale, R; Rossi, G; Ruggeri, M; Siragusa, S; Vianelli, N | 1 |
| Baydildina, DD; Kalinina, II; Maschan, AA; Novichkova, GA; Petrova, UN; Pshonkin, AV; Suntsova, EV | 1 |
| Atkinson, K | 1 |
| Gernsheimer, TB; Poston, JN | 1 |
| Bussel, JB; Cooper, N; Ghanima, W; Godeau, B; Rodeghiero, F | 1 |
| Roongta, R; Sanil, S; Shobha, V | 1 |
| Neunert, CE; Rose, MJ | 1 |
| Caputo, I; D'Amore, F; Da Dalt, G; Friziero, A; Lombardi, AM; Vianello, F | 1 |
| Barcellini, W; Cassin, R; Fattizzo, B; Levati, G | 1 |
| Bussel, JB; Guo, X; West, RB; Xu, L; You, X; Zehnder, JL; Zhang, BM; Zhang, H | 1 |
| Baldacci, E; Canichella, M; Chistolini, A; Di Rocco, A; Ferretti, A; Foà, R; Gabriella Mazzucconi, M; Martelli, M; Miulli, E; Pulsoni, A; Santoro, C; Serrao, A | 1 |
| D'Arena, G; Guariglia, R; Lerose, R; Mansueto, G; Martorelli, MC; Musto, P; Pietrantuono, G; Villani, O | 1 |
| Abgrall, JF; Audia, S; Bierling, P; Boutboul, D; Cheze, S; Dauriac, C; Durand, JM; Fain, O; Godeau, B; Gyan, E; Hamidou, M; Khellaf, M; Languille, L; Lefort, S; Lefrere, F; Michel, M; Michot, JM; Niault, M; Roudot-Thoraval, F; Viallard, JF | 1 |
| Arnold, DM; Ghadaki, B; Kelton, JG; Nazi, I | 1 |
| Brainsky, A; Fogarty, P; Mayer, B; Tarantino, MD; Vasey, SY | 1 |
| Deveci, B; Karakuş, V; Kurtoğlu, E | 1 |
| Hallam, S; Newland, AC; Provan, D | 1 |
| Hino, M; Kanashima, H; Kumura, T; Manabe, M; Nakane, T; Nakao, T; Ogawa, Y; Ohta, T; Yamamura, R; Yamane, T; Yoshida, M | 1 |
| Amaddii, G; Billio, A; Cortelazzo, S; Natolino, F; Piccin, A | 1 |
| Aotsuka, N; Hara, S; Imai, H; Inokuchi, K; Koizumi, M; Komatsu, T; Kumagai, K; Matsuura, Y; Nakaseko, C; Takeuchi, M; Tanaka, H; Tsukamoto, S; Wakita, H; Yokota, A | 1 |
| Kuter, DJ; Makar, RS; Sahud, MA; Zhukov, OS | 1 |
| Au, WY; Chow, PC; Kan, YT; Ma, ES | 1 |
| Candiotto, L; Ruggeri, M; Sartori, R; Tagariello, G | 1 |
| Brainsky, A; Fogarty, PF; Shah, P; Tarantino, MD | 1 |
| Akehurst, R; Cooper, K; Helme, K; Matcham, J | 1 |
| Alonso, A; Arefi, M; Barez, A; Calbacho, M; de Cabo, E; Galan, P; González-López, TJ; González-Porras, JR; Jiménez-Bárcenas, R; Martín-Salces, M; Pascual, C; Sánchez-González, B | 1 |
| Alvarez Román, MT; Arias-Salgado, EG; Butta, NV; Fernández Bello, I; Jiménez Yuste, V; Martín Salces, M; Rivas Pollmar, MI | 1 |
| Mishra, S; Shukla, A; Tripathi, AK; Yadav, DK; Yadav, YS | 1 |
| Álvarez Román, MT; Arias-Salgado, EG; Butta, NV; de Paz, R; Fernández Bello, I; Jiménez Yuste, V; Martín Salces, M | 1 |
| Bierling, P; Ebbo, M; Fain, O; Godeau, B; Khellaf, M; Languille, L; Limal, N; Mahévas, M; Michel, M; Roudot-Thoraval, F; Schleinitz, N | 1 |
| Katayama, Y; Komada, T; Kusagawa, H; Shomura, S | 1 |
| Cantú-Rodríguez, OG; Gómez-Almaguer, D; Gómez-De León, A; Gutiérrez-Aguirre, CH; Hernández-Reyes, J; Herrera-Rojas, MA; Jaime-Pérez, JC; Ruiz-Arguelles, GJ; Tarín-Arzaga, L | 1 |
| Arumugaswamy, A; Brotchie, J; Grigg, A; He, S; Quach, H | 1 |
| Bussel, JB; Hsieh, L; Leven, E; Nugent, D; Ramaswamy, K; Thompson, MV | 1 |
| Buchanan, GR | 1 |
| Catani, L; Palandri, F; Polverelli, N; Sollazzo, D; Vianelli, N | 1 |
| Jolliffe, E; Romeril, K | 1 |
| Boulad, N; Bussel, JB; Edison, MN; Josefsson, EC; Kaplan, D; Karpoff, M; Kile, BT; Mitchell, WB; Pinheiro, MP; Psaila, B; White, MJ | 1 |
| Boura, P; Hatzitolios, A; Kaiafa, G; Onoufriadis, I; Perifanis, V; Sousos, N; Vlachaki, E | 1 |
| Cervera, R; Enríquez, H; Espinosa, G; Esteve, J; Magnano, L | 1 |
| Kashiwagi, H; Tomiyama, Y | 1 |
| De Fabritiis, P; Giovannini, M; Niscola, P; Perrotti, A; Scaramucci, L; Tendas, A | 1 |
| Aguilar, C; Alonso, A; Alonso, R; Álvarez-Román, MT; Andrade, MM; Arratibel, MC; Beneit, P; Bernat, S; Calbacho, M; Caparrós, I; Casaus, A; Coria, E; Cortés, M; Cortti, MJ; de Cabo, E; de Cos, C; Fernández-Canal, C; Fernández-Fuertes, F; Fernández-Miñano, C; Fernández-Rodríguez, A; Fisac, R; Fuertes-Palacio, MA; Galán, P; Garcia-Frade, J; Gómez-Núñez, M; González-López, TJ; González-Porras, JR; González-Silva, M; Gutierrez-Jomarrón, I; Hernández-Rivas, JA; Jarque, I; Jiménez, R; Luaña, A; Martín-Salces, M; Martínez-Robles, V; Mingot-Castellano, ME; Olivera, PE; Pascual, C; Paz Martínez-Badas, M; Peñarrubia, MJ; Perera, M; Pérez-Crespo, S; Pérez-Rus, G; Sainz, A; Sánchez-González, B; Solán, L; Valcarce, I; Vázquez-Paganini, JA | 1 |
| Andersen, JC; Dhar, JP; Maroun, MC; Ososki, R | 1 |
| El Rassy, E; Georges, S; Haddad, E; Kourie, HR; Nasnas, R; Nasr, F; Nehme, W | 1 |
| Alonso, R; Alvarez-Román, MT; Andrade, MM; Arratibel, MC; Bernat, S; Calbacho, M; Caparrós, I; Cortés, M; Cortti, MJ; Díaz-Gálvez, FJ; Fernández-Fuertes, F; Fernández-Miñano, C; Fuertes-Palacio, MA; Garcia-Frade, J; González-López, TJ; González-Porras, JR; Jarque, I; Martínez-Robles, V; Mingot-Castellano, ME; Olivera, PE; Pascual, C; Sánchez-González, B; Vázquez-Paganini, JA | 1 |
| Dawson, KL; Grotzinger, KM; Kuter, DJ; Macahilig, C; Poston, SA; Wang, PF; Ward, M | 1 |
| Bilgin, R; Karaselek, MA; Uğur Bilgin, A | 1 |
| Avorn, J; Franklin, JM; Kesselheim, AS; Landon, JE; Sarpatwari, A; Seeger, JD | 1 |
| Hattori, H; Karasuno, T; Kuwayama, M; Nishiura, N; Takamori, H | 1 |
| Bailey, CK; Bakshi, KK; Brynes, RK; Burgess, P; Orazi, A; Thein, MM; Theodore, D | 1 |
| Akgün Çağlıyan, G; Alacacıoğlu, İ; Arslan, Ö; Bilgir, O; Bolaman, Z; Büyükkeçeci, F; Ceylan, C; Gökgöz, Z; Görgün, G; Kabukçu, G; Kabukçu, S; Kadıköylü, G; Kahraman, S; Keskin, A; Kiper, HD; Özcan, MA; Özdemirkıran, F; Payzın, B; Şahin, F; Saydam, G; Sevindik, ÖG; Tombuloğlu, M; Vural, F | 1 |
| Farrell, C; Guo, H; Hayes, S; Hou, M; Thapar, M; Wu, K; Zhang, J | 1 |
| Hanada, R; Kato, M; Koh, K; Mori, M | 1 |
| Bailey, CK; Bakshi, KK; Bussel, JB; Chagin, KD; Chan, GW; Chotsampancharoen, T; Donyush, E; Drelichman, G; Grainger, JD; Holzhauer, S; Iyengar, M; Komvilaisak, P; Lebedev, V; Lemons, R; Locatelli, F; Marcello, LM; Pongtanakul, B; Pospisilova, D; Ramenghi, U; Sirachainan, N; Sosothikul, D; Theodore, D | 1 |
| Grace, RF; Neunert, CE | 1 |
| Eser, A; Firatli-Tuglular, T; Kara, O; Kaygusuz-Atagunduz, I; Noyan-Atalay, F; Ozgumus, T; Pepedil-Tanrikulu, F; Sezgin, A; Toptas, T; Yilmaz, G | 1 |
| Locatelli, F; Merli, P; Palumbo, G; Strocchio, L; Vinti, L | 1 |
| Boulon, C; Constans, J; Vircoulon, M | 1 |
| Audia, S; Bonnotte, B; Godeau, B | 1 |
| Bai, LY; Chang, YF; Chen, CG; Chen, TY; Chiou, TJ; Hsueh, EJ; Kao, CW; Lan, YJ; Lin, HY; Lin, SF; Sung, YC; Wang, MC | 1 |
| Arai, N; Ariizumi, H; Fujiwara, S; Harada, H; Hattori, N; Kabasawa, N; Kawaguchi, Y; Mori, H; Nakamaki, T; Saito, B; Shiozawa, E; Tsukamoto, H; Uto, Y; Yanagisawa, K | 1 |
| Rodeghiero, F | 2 |
| Cascavilla, N; Di Renzo, N; Mazza, P; Melpignano, A; Minoia, C; Polimeno, G; Specchia, G | 1 |
| Li, AM; Wang, XL | 1 |
| Bailey, CK; Bakshi, KK; Blanchette, VS; Boayue, KB; Bussel, JB; Chagin, KD; Chan, GW; Connor, P; David, M; de Miguel, PG; Despotovic, JM; Grainger, JD; Iyengar, M; Krishnamurti, L; Lambert, MP; Marcello, LM; Matthews, DC; Sevilla, J; Theodore, D | 1 |
| Aguilar, C; Alvarez-Román, MT; Andrade, MM; Bárez, A; Bernat, S; Cortés, M; de Cabo, E; Fernández-Fuentes, F; Fernández-Miñano, C; Fernández-Rodríguez, A; Fisac, R; Fuertes-Palacio, MA; García-Frade, LJ; Gómez-Nuñez, M; González-López, TJ; González-Porras, JR; Hernández-Rivas, JA; Jarque, I; Martínez-Robles, V; Olivera, P; Pascual, C; Peñarrubia, MJ; Pérez-Crespo, S; Pérez-Rus, G; Sánchez-González, B | 1 |
| Grainger, JD | 1 |
| Drysdale, H; Milosevic, I; Slade, E | 1 |
| Barcellini, W; Cantoni, S; Caparrotti, G; Carpenedo, M; Carrai, V; Crea, E; Di Nicola, M; Di Renzo, N; Fanin, R; Ferla, V; Liberati, AM; Paoloni, F; Santoro, C; Simonetti, F; Tuniz, E; Veneri, D; Volpetti, S; Zaja, F | 1 |
| Miyahara, M; Ureshino, H | 1 |
| Barcellini, W; Carrabba, M; Fabio, G | 1 |
| Fabritiis, Pd; Giovannini, M; Niscola, P; Palombi, M; Scaramucci, L; Tendas, A | 1 |
| Bennett, C; Brown, T; Despotovic, J; Forbes, PW; Grace, RF; Haley, K; Klaassen, R; Lambert, MP; Neunert, C; Nottage, K; Pastore, Y; Shimano, K; Stine, K; Thompson, A | 1 |
| Burness, CB; Garnock-Jones, KP; Keating, GM | 1 |
| Abe, R; Fujiwara, N; Horikoshi, A; Ito, E; Takaku, T; Tsukuda, J | 1 |
| Chen, P; Dong, XY; Feng, Q; Gao, C; Hou, M; Li, GS; Liu, S; Liu, XG; Liu, XN; Liu, Y; Ma, C; Peng, J; Qin, P; Sheng, Z; Wei, Y; Zhang, L | 1 |
| Ashal, GE; Elfil, M; Elgebaly, AS; Menshawy, A | 1 |
| Brighton, TA; Joseph, JE; Matthews, GV; Simpson, JD | 1 |
| Bermejo, N; Ibáñez, F; Sigüenza, R | 1 |
| Grenda, R; Jarmużek, W; Latoszyńska, J; Prokurat, S; Rubik, J | 1 |
| Bardy, G; Bernard, N; Cathébras, P; Default, A; Durieu, I; Geniaux, H; Godeau, B; Guy, C; Hunault, M; Jonville-Bera, AP; Lioger, B; Mahévas, M; Moachon, L; Moulis, G; Pérault-Pochat, MC; Ramanantsoa, M; Royer, B; Weber, E | 1 |
| Özdil, H; Sert, S; Sünbül, M | 1 |
| DaRos, CV; González, KJ; Martí, AC; Rodríguez, PP; Zuluaga, SO | 1 |
| Bakshi, KK; Brynes, RK; Burgess, P; Orazi, A; Thein, MM; Theodore, D; Wong, RS | 1 |
| Ostojic, SK; Rogulj, IM; Vibor, M | 1 |
| Feng, Q; Hou, M; Li, GS; Liu, S; Liu, XG; Liu, XN; Liu, Y; Lv, MY; Peng, J; Qu, MM; Zhang, L; Zhang, X; Zhu, YY | 1 |
| Kwiatkowski, JL; Lambert, MP; Witmer, CM | 1 |
| Demina, IM; Dobrynina, J; Ershov, NM; Hachatryan, LA; Ignatova, AA; Kotskaya, NN; Maschan, AA; Novichkova, GA; Orekhova, EV; Panteleev, MA; Pshonkin, AV; Serkova, IV; Suntsova, EV; Supik, ZS; Trubina, NM | 1 |
| Laskou, F; McGuckin, S; Scully, M; Taylor, A; Westwood, JP | 1 |
| Jackson, SP; Wei, A | 1 |
| Tomiyama, Y | 2 |
| Arnason, JE; Bussel, JB; Levy, B | 1 |
| Godeau, B | 1 |
| Burzynski, J | 1 |
| Morrow, T | 1 |
| Francesco, R | 1 |
| Pabinger, I; Panzer, S | 1 |
| Arning, M; Bussel, JB; Cheng, G; Jenkins, JM; Kovaleva, L; Mayer, B; Provan, D; Psaila, B; Roychowdhury, D; Salama, A; Shamsi, T; Stone, N | 1 |
| Vadhan-Raj, S | 1 |
| Nurden, AT; Nurden, P; Viallard, JF | 1 |
| Panzer, S | 2 |
| Garnock-Jones, KP; Keam, SJ | 1 |
| Diez-Ewald, M; Vizcaíno, G; Vizcaíno-Carruyo, J | 1 |
| Arnold, DM; Kelton, JG; Nazi, I | 1 |
| Hussar, DA | 1 |
| Lam, MS | 1 |
| Newland, A | 3 |
| Miyakawa, Y | 1 |
| Dmytrijuk, A; Pazdur, R; Rieves, D; Robie-Suh, K | 1 |
| Bussel, JB | 1 |
| Molineux, G; Newland, A | 1 |
| Keating, MJ; Koehrer, S; Wierda, WG | 1 |
| Olsson, B; Wadenvik, H | 1 |
| Chitlur, M; Nugent, DJ; Roganovic, J; Tamary, H | 1 |
| Imbach, P; Kühne, T | 1 |
| Ferrer-Marin, F; Gutti, RK; Liu, ZJ; Sallmon, H; Sola-Visner, MC | 1 |
| Giagounidis, A; Greinacher, A; Hiller, E; Kiefel, V; Matzdorff, A; Müller-Beissenhirtz, H; Ostermann, H; Rummel, M; Sachs, UJ; Salama, A | 1 |
| Chouhan, JD; Herrington, JD | 1 |
| Sperati, CJ; Streiff, MB | 1 |
| Gibiansky, E; Ouellet, D; Wang, Z; Williams, D; Zhang, J | 1 |
| Cook, L; Cooper, N | 1 |
| Aivado, M; Arning, M; Bussel, JB; Cheng, G; Marcher, C; Mayer, B; Saleh, MN; Stone, NL; Vasey, S | 1 |
| Nurden, AT | 1 |
| Stasi, R | 2 |
| Gibiansky, E; Hayes, S; Ouellet, D; Wire, MB; Zhang, J | 1 |
| Birgens, HS; Frederiksen, H; Gudbrandsdottir, S; Hasselbalch, HC; Nielsen, CH; Nielsen, OJ; Stentoft, J | 1 |
| Benham, L; Guo, L; Turner, R | 1 |
| Meyer, O; Salama, A | 1 |
| Barsam, SJ; Beer, JH; Bussel, JB; Forestier, M; Gernsheimer, TB; Geyer, JT; Page, LK; Psaila, B; Ruisi, MM; Sloane, PA; Villarica, GO | 1 |
| Horikawa, M; Ishiwata, N; Kato, Y; Matsubara, K; Nakamichi, N; Silver, DL; Sugiura, T; Takeuchi, K; Umeda, S | 1 |
| Fukunaga, S; Hori, A; Ono, S; Tanimoto, T; Yagasaki, F | 1 |
| Abadie, E; Brown, D; Calvo, G; Feldschreiber, P; Hudson, I; Lay, G; Lee, CC; Nieto, M; Pignatti, F; Thomas, A; Valeri, A | 1 |
| Duan, X; Ni, X; Xu, J; Zeng, Y | 1 |
| Garnock-Jones, KP | 2 |
| Boiocchi, L; Bussel, JB; Feng, X; Geyer, JT; Ghanima, W; Gudbrandsdottir, S; Hasselbalch, HC; Junker, P; Orazi, A | 1 |
| Kolesar, JM; Zhang, Y | 1 |
| Bolton-Maggs, PH; Collins, R; Emohare, O; Kaczmarski, R; Myers, B; Scully, M | 1 |
| Frederiksen, H; Gudbrandsdottir, S; Hasselbalch, H | 1 |
| Fernández, A; Grande, C; Jarque, I; López, MF; Martínez, R; Mingot, ME; Monteagudo, E; Ribera, JM; Sanz, MÁ; Valcárcel, D; Vicente García, V | 1 |
| Babula, B; Barnard, MR; Bussel, JB; Frelinger, AL; Li, Y; Linden, MD; Mathur, K; Michelson, AD; Psaila, B; Tate, C | 1 |
| Hattori, T; Ikeda, Y; Kanakura, Y; Katsura, K; Katsutani, S; Kimura, A; Kosugi, H; Miyakawa, Y; Ninomiya, H; Nomura, S; Okamoto, S; Okoshi, Y; Ozaki, K; Tomiyama, Y | 1 |
| Boyers, D; Jenkinson, D; Jia, X; Mowatt, G | 2 |
| Aoki, T; Harada, Y; Kasai, M; Matsubara, E; Ogura, M; Oyama, T; Suzuki, T; Uchida, T | 1 |
| Altomare, I; Pullarkat, V; Wasser, J | 1 |
| Barsam, S; Bussel, JB; Ghanima, W; Lee, SY; Miller, A; Sandset, PM | 1 |
| Ruggeri, M | 1 |
| Arnold, DM | 2 |
| Joshi, A; Noronha, V; Philip, SD; Prabhash, K | 1 |
| Aggarwal, S; Randhawa, H; Sharma, A; Sharma, V | 1 |
| Akehurst, R; Cooper, KL; Dillingham, K; Fitzgerald, P; Helme, K | 1 |
| Flores, B; Jonsson, B; Pignatti, F | 1 |
| Holbro, A; Meyer, SC; Rovó, A; Scherer, K; Tichelli, A; Tsakiris, DA | 1 |
| Basciano, PA; Bussel, J; Christos, PJ; Giannakakou, P; Hafeez, Z | 1 |
| Arning, M; Bailey, CK; Brainsky, A; Bussel, JB; Cheng, G; Meyer, O; Saleh, MN | 1 |
| Aisa, Y; Ito, C; Mihara, A; Nakazato, T | 1 |
| Arning, M; Bussel, JB; Mayer, B; Saleh, MN; Stone, NL; Vasey, SY | 1 |
| Levitov, AB; Mulla, CM; Rashidi, A | 1 |
| Akay, OM; Andic, N; Gunduz, E; Şahin, D; Teke, HÜ | 1 |
| Chumsri, S; Zimrin, A | 1 |
| Allen, R; Brainsky, A; Grotzinger, K; Roccia, T | 1 |
| Haselboeck, J; Kaider, A; Pabinger, I; Panzer, S | 1 |
| Kurata, Y | 1 |
| Arning, M; Bussel, JB; Cheng, G; Hassani, H; Jenkins, JM; Kloczko, J; Kovaleva, L; Mayer, B; Meddeb, B; Provan, D; Psaila, B; Saleh, MN; Stone, NL | 1 |
| Schwartz, RS | 1 |
| Abrams, CS; Metjian, A | 1 |
| Kuter, DJ | 1 |
| Amadori, S; Buccisano, F; Evangelista, ML; Stasi, R; Stipa, E; Venditti, A | 1 |
| Andrès, E; Hentges, F; Zimmer, J | 1 |
| Amadori, S; Evangelista, ML; Stasi, R | 1 |
| Bussel, JB; Kobos, R | 1 |
71 review(s) available for hydrazine and Autoimmune Thrombocytopenia
| Article | Year |
|---|---|
Thrombopoietin receptor agonists and rituximab for treatment of pediatric immune thrombocytopenia: A systematic review and meta-analysis of prospective clinical trials.
Topics: Benzoates; Child; Humans; Hydrazines; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Rituximab; Thrombocytopenia; Thrombopoietin | 2022 |
Comparative efficacy of 19 drug therapies for patients with idiopathic thrombocytopenic purpura: a multiple-treatments network meta-analysis.
Topics: Benzoates; Dexamethasone; Humans; Hydrazines; Network Meta-Analysis; Purpura, Thrombocytopenic, Idiopathic; Rituximab; Thrombopoietin | 2022 |
Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem.
Topics: Antineoplastic Agents; Benzoates; Hemorrhage; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2022 |
Efficacy and Incidence of Treatment-Related Adverse Events of Thrombopoietin Receptor Agonists in Adults with Immune Thrombocytopenia: A Systematic Review and Network Meta-Analysis of Randomized Controlled Study.
Topics: Adult; Benzoates; Humans; Hydrazines; Incidence; Network Meta-Analysis; Purpura, Thrombocytopenic, Idiopathic; Randomized Controlled Trials as Topic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2023 |
Eltrombopag in severe immune thrombocytopenia secondary to connective tissue disease: a report of 17 patients and literature review.
Topics: Benzoates; Connective Tissue Diseases; Humans; Hydrazines; Immunosuppressive Agents; Leukopenia; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia; Treatment Outcome | 2023 |
European Delphi panel to build consensus on tapering and discontinuing thrombopoietin receptor agonists in immune thrombocytopenia.
Topics: Benzoates; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2023 |
Catastrophic antiphospholipid syndrome in lupus-associated immune thrombocytopenia treated with eltrombopag A case series and literature review.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Benzoates; Female; Humans; Hydrazines; Lupus Erythematosus, Systemic; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia | 2023 |
Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus.
Topics: Adult; Benzoates; Consensus; COVID-19; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2023 |
Efficacy and safety of thrombopoietin receptor agonists in children and adults with persistent and chronic immune thrombocytopenia: a meta-analysis.
Topics: Adult; Benzoates; Child; Hemorrhage; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Receptors, Thrombopoietin; Recombinant Fusion Proteins | 2023 |
Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis.
Topics: Adult; Benzoates; Drug Therapy, Combination; Female; Humans; Hydrazines; Male; Platelet Count; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thrombopoietin | 2020 |
Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
Topics: Adolescent; Age Factors; Benzoates; Blood Platelets; Child; Child, Preschool; Evidence-Based Medicine; Female; Humans; Hydrazines; Infant; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Signal Transduction; Thrombopoietin; Treatment Outcome | 2021 |
Autoimmune pancytopenia following chronic immune thrombocytopenia: Case report and literature review.
Topics: Aged; Benzoates; Bone Marrow; Chronic Disease; Cyclosporine; Humans; Hydrazines; Immunologic Factors; Immunosuppressive Agents; Male; Pancytopenia; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Rituximab | 2020 |
[Adult immune thrombocytopenia and thrombopoietin receptor agonist: Ten years later].
Topics: Adult; Autoimmunity; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin; Thrombosis | 2021 |
A practical guide to the use of eltrombopag in children with chronic immune thrombocytopenia.
Topics: Adolescent; Benzoates; Child; Child, Preschool; Chronic Disease; Female; Humans; Hydrazines; Infant; Infant, Newborn; Male; Practice Guidelines as Topic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2017 |
Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review.
Topics: Benzoates; Child; Hemorrhage; Humans; Hydrazines; Incidence; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2017 |
Eltrombopag for use in children with immune thrombocytopenia.
Topics: Benzoates; Child; Hemorrhage; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2018 |
Immune thrombocytopenic purpura associated with Crohn's disease with complete response to infliximab.
Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Azathioprine; Benzoates; Crohn Disease; Humans; Hydrazines; Immunosuppressive Agents; Infliximab; Male; Middle Aged; Pancreatitis; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Remission Induction | 2019 |
Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: A systematic review incorporating an indirect-comparison meta-analysis.
Topics: Adult; Benzoates; Blood Platelets; Hemorrhage; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin; Treatment Outcome | 2018 |
Thrombopoietin receptor agonists in hereditary thrombocytopenias.
Topics: Benzoates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Genetic Association Studies; Genetic Heterogeneity; Genetic Predisposition to Disease; Hematologic Neoplasms; Humans; Hydrazines; Primary Myelofibrosis; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Risk; Thrombocytopenia; Thrombophilia; Thrombopoiesis; Thrombopoietin | 2018 |
Systematic literature review of treatments used for adult immune thrombocytopenia in the second-line setting.
Topics: Adult; Benzoates; Case-Control Studies; Cohort Studies; Combined Modality Therapy; Double-Blind Method; Drug Therapy, Combination; Humans; Hydrazines; Immunosuppressive Agents; Multicenter Studies as Topic; Observational Studies as Topic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Splenectomy; Thrombopoietin | 2019 |
Management of immune thrombocytopenia in elderly patients.
Topics: Aged; Benzoates; Humans; Hydrazines; Immunoglobulins, Intravenous; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Rituximab; Splenectomy; Thrombopoietin | 2018 |
Thrombopoietin Receptor Agonist Use for Immune Thrombocytopaenia.
Topics: Administration, Oral; Adult; Benzoates; Child; Child, Preschool; Clinical Trials as Topic; Hemorrhage; Humans; Hydrazines; Immunosuppression Therapy; Infant; Infant, Newborn; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Quality of Life; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Safety; Splenectomy; Thrombopoiesis; Thrombopoietin | 2019 |
Successful discontinuation of eltrombopag in one child with refractory primary immune thrombocytopenia and literature review.
Topics: Benzoates; Child; Female; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Substance Withdrawal Syndrome; Treatment Outcome | 2019 |
Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
Topics: Adult; Benzoates; Child; Chronic Disease; Humans; Hydrazines; Patient Education as Topic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2019 |
Thrombopoietin receptor agonists: ten years later.
Topics: Animals; Benzoates; Biomarkers; Blood Coagulation; Clinical Trials as Topic; Disease Susceptibility; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Signal Transduction; Thrombopoietin; Treatment Outcome | 2019 |
Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice.
Topics: Adrenal Cortex Hormones; Benzoates; Child, Preschool; Clinical Trials as Topic; Cloning, Organism; Drug Development; Hemorrhage; History, 20th Century; Humans; Hydrazines; Immunoglobulins; Infant; Injections, Subcutaneous; Platelet Count; Practice Guidelines as Topic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Safety; Splenectomy; Thrombocytopenia, Neonatal Alloimmune; Thrombopoietin; United States; United States Food and Drug Administration | 2019 |
Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation.
Topics: Anemia, Aplastic; Benzoates; Humans; Hydrazines; Immunomodulation; Immunosuppression Therapy; Megakaryocytes; Myelodysplastic Syndromes; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2019 |
Immune thrombocytopenia -- what are the new treatment options?
Topics: Benzoates; Disease Management; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2013 |
[Management of idiopathic thrombocytopenic purpura (primary immune thrombocytopenia, ITP)].
Topics: Antibodies, Monoclonal, Murine-Derived; Benzoates; Biomarkers; Dexamethasone; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Hydrazines; Platelet Glycoprotein GPIb-IX Complex; Platelet Glycoprotein GPIIb-IIIa Complex; Prednisolone; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Rituximab; Splenectomy; Thrombopoietin | 2014 |
Eltrombopag for treatment of thrombocytopenia-associated disorders.
Topics: Anemia, Aplastic; Animals; Benzoates; Chronic Disease; Clinical Trials as Topic; Hematopoietic Stem Cell Transplantation; Hepatitis, Chronic; Humans; Hydrazines; Myelodysplastic Syndromes; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Thrombopoiesis | 2015 |
Is ITP a thrombophilic disorder?
Topics: Benzoates; Humans; Hydrazines; Incidence; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Risk; Splenectomy; Thrombopoietin; Thrombosis | 2016 |
Successful use of eltrombopag in a child with refractory immune thrombocytopenia: case study and literature review.
Topics: Benzoates; Child; Female; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2016 |
Eltrombopag: A Review in Paediatric Chronic Immune Thrombocytopenia.
Topics: Adolescent; Benzoates; Blood Platelets; Child; Child, Preschool; Chronic Disease; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Double-Blind Method; Hemorrhage; Humans; Hydrazines; Infant; Multicenter Studies as Topic; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Thrombopoietin | 2016 |
Tolerability and Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia: Meta-Analysis of Randomized Controlled Trials.
Topics: Adolescent; Adult; Benzoates; Child; Child, Preschool; Chronic Disease; Female; Humans; Hydrazines; Infant; Male; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic | 2017 |
Is there any Role for Splenectomy in Adulthood Onset Chronic Immun e Thrombocytopenia in the Era of TPO Receptors Agonists? A Critic al Overview.
Topics: Adult; Benzoates; Blood Platelets; Chronic Disease; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Splenectomy; Thrombopoietin | 2017 |
[Autoimmune (idiopathic) thrombocytopenic purpura].
Topics: Acute Disease; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Autoantibodies; Benzoates; Biomarkers; Blood Platelets; Chronic Disease; Female; Humans; Hydrazines; Immunoglobulin G; Immunosuppressive Agents; Male; Platelet Glycoprotein GPIb-IX Complex; Platelet Glycoprotein GPIIb-IIIa Complex; Prednisolone; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Rituximab; Splenectomy | 2008 |
The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopenia.
Topics: Benzoates; Blood Platelets; Carrier Proteins; Chronic Disease; Clinical Trials as Topic; Hemorrhage; Hepatitis C; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoiesis; Thrombopoietin; Treatment Outcome | 2008 |
Two new drugs for chronic ITP.
Topics: Benzoates; Carrier Proteins; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin | 2009 |
Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents.
Topics: Benzoates; Carrier Proteins; Clinical Trials as Topic; Humans; Hydrazines; Interleukin-11; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoiesis; Thrombopoietin | 2009 |
New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura.
Topics: Benzoates; Carrier Proteins; Chronic Disease; Drug Approval; Hemorrhage; Humans; Hydrazines; Megakaryocytes; Methacrylates; Patient Selection; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Safety; Thiazoles; Thiophenes; Thrombopoiesis; Thrombopoietin; Treatment Outcome; United States; United States Food and Drug Administration | 2009 |
Eltrombopag in chronic idiopathic thrombocytopenic purpura and HCV-related thrombocytopenia.
Topics: Benzoates; Chronic Disease; Dose-Response Relationship, Drug; Hepacivirus; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2009 |
[Treatment of chronic immune thrombocytopenic purpura. Looking for something better. Review].
Topics: Adrenal Cortex Hormones; Antigens, Human Platelet; Autoantibodies; Benzoates; Blood Platelets; Clinical Trials as Topic; Combined Modality Therapy; Cost-Benefit Analysis; Dapsone; Helicobacter Infections; Helicobacter pylori; Humans; Hydrazines; Immunoglobulins, Intravenous; Immunologic Factors; Immunosuppressive Agents; Models, Immunological; Molecular Mimicry; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Splenectomy; Thrombopoiesis | 2009 |
New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Benzoates; Blood Platelets; Carrier Proteins; Drugs, Investigational; Humans; Hydrazines; Immunologic Factors; Models, Biological; Models, Immunological; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Rituximab; Thrombopoietin | 2009 |
Review article: second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults.
Topics: Adult; Animals; Benzoates; Chronic Disease; Controlled Clinical Trials as Topic; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Thrombopoietin | 2010 |
Thrombopoietin receptor agonists in the treatment of thrombocytopenia.
Topics: Benzoates; Carrier Proteins; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2009 |
[Development of thrombopoietin receptor agonists].
Topics: Animals; Benzoates; Clinical Trials as Topic; Drug Discovery; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Signal Transduction; Thrombocytopenia; Thrombopoietin | 2009 |
Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside.
Topics: Adult; Aged; Aged, 80 and over; Animals; Benzoates; Chronic Disease; Clinical Trials as Topic; Drug Discovery; History, 18th Century; History, 19th Century; History, 20th Century; History, 21st Century; Humans; Hydrazines; Mice; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin; Young Adult | 2010 |
Moving towards a new era in the management of chronic immune thrombocytopenia.
Topics: Benzoates; Chronic Disease; Hemorrhage; Hydrazines; Medication Therapy Management; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2010 |
Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
Topics: Benzoates; Hemorrhage; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Thrombopoietin | 2010 |
Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Benzoates; Chronic Disease; Clinical Trials, Phase III as Topic; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thrombopoiesis; Thrombopoietin | 2010 |
Eltrombopag--a novel approach for the treatment of chronic immune thrombocytopenic purpura: review and safety considerations.
Topics: Animals; Benzoates; Blood Platelets; Chronic Disease; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic | 2010 |
Eltrombopag for the treatment of idiopathic thrombocytopenic purpura.
Topics: Benzoates; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Thrombopoiesis | 2008 |
The European Medicines Agency review of eltrombopag (Revolade) for the treatment of adult chronic immune (idiopathic) thrombocytopenic purpura: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
Topics: Adult; Animals; Benzoates; Clinical Trials, Phase III as Topic; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Risk Assessment; Treatment Outcome | 2011 |
TPO receptor agonist for chronic idiopathic thrombocytopenic purpura.
Topics: Benzoates; Chronic Disease; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2011 |
Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia.
Topics: Adult; Animals; Benzoates; Chronic Disease; Drug Interactions; Hemorrhage; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Time Factors | 2011 |
[Management of refractory ITP with thrombopoietin receptor agonists].
Topics: Animals; Benzoates; Clinical Trials as Topic; Drug Design; Humans; Hydrazines; Molecular Targeted Therapy; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Recombinant Proteins; Thrombopoietin | 2011 |
Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.
Topics: Benzoates; Chronic Disease; Clinical Trials as Topic; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2011 |
Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura.
Topics: Benzoates; Drug Interactions; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2011 |
Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal.
Topics: Benzoates; Cost-Benefit Analysis; Decision Making; Humans; Hydrazines; Models, Economic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Splenectomy; Technology Assessment, Biomedical; Thrombopoietin; Time Factors | 2012 |
Bleeding and mortality outcomes in ITP clinical trials: a review of thrombopoietin mimetics data.
Topics: Benzoates; Clinical Trials as Topic; Hemorrhage; Humans; Hydrazines; Incidence; Platelet Count; Proportional Hazards Models; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Research Design; Standard of Care; Thrombopoietin; Treatment Outcome | 2012 |
Eltrombopag--an oral thrombopoietin agonist.
Topics: Administration, Oral; Benzoates; Humans; Hydrazines; Liver Cirrhosis; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2012 |
Romiplostim and eltrombopag for immune thrombocytopenia: methods for indirect comparison.
Topics: Bayes Theorem; Benzoates; Databases, Factual; Female; Humans; Hydrazines; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin | 2012 |
Positioning new treatments in the management of immune thrombocytopenia.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Benzoates; Blood Platelets; Child; Hemorrhage; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Rituximab; Thrombopoiesis; Thrombopoietin | 2013 |
[Recent advances in the treatment of idiopathic thrombocytopenic purpura].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Benzoates; Carrier Proteins; Clinical Trials as Topic; Helicobacter Infections; Helicobacter pylori; Humans; Hydrazines; Immunoglobulin G; Laparoscopy; Platelet Transfusion; Practice Guidelines as Topic; Prednisolone; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Splenectomy; Thrombopoietin | 2007 |
New therapeutic options for adult chronic immune thrombocytopenic purpura: a brief review.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antilymphocyte Serum; B-Lymphocytes; Benzoates; Carrier Proteins; Chronic Disease; Clinical Trials as Topic; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Splenectomy; Thrombopoietin | 2008 |
New insights and therapeutics for immune-mediated thrombocytopenia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Benzoates; Carrier Proteins; CD40 Ligand; Dexamethasone; Humans; Hydrazines; Immunosuppressive Agents; Molecular Mimicry; Polyethylene Glycols; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Recombinant Proteins; Rituximab; Thrombopoiesis; Thrombopoietin | 2008 |
New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.
Topics: Antibodies, Monoclonal; Benzoates; Blood Platelets; Carrier Proteins; Humans; Hydrazines; Polyethylene Glycols; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Recombinant Proteins; Thrombopoiesis; Thrombopoietin | 2008 |
Emerging strategies to treat chronic immune thrombocytopenic purpura.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Benzoates; Chronic Disease; Humans; Hydrazines; Immunoglobulins, Intravenous; Intercellular Signaling Peptides and Proteins; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Rituximab; Splenectomy; Thrombopoiesis; Thrombopoietin | 2008 |
Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management.
Topics: Animals; Autoantibodies; B-Lymphocytes; Benzoates; Blood Platelets; Carrier Proteins; Cell Communication; Glucocorticoids; Hematologic Agents; Humans; Hydrazines; Immune Tolerance; Immunoglobulins, Intravenous; Immunologic Factors; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Splenectomy; T-Lymphocytes; Thrombopoiesis; Thrombopoietin; Treatment Failure | 2008 |
Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura.
Topics: Benzoates; Carrier Proteins; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoiesis; Thrombopoietin | 2008 |
Overview of thrombopoietic agents in the treatment of thrombocytopenia.
Topics: Animals; Benzoates; Carrier Proteins; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Recombinant Proteins; Thrombocytopenia; Thrombopoiesis; Thrombopoietin | 2008 |
30 trial(s) available for hydrazine and Autoimmune Thrombocytopenia
| Article | Year |
|---|---|
A phase 3, randomized, double-blind, active-controlled trial evaluating efficacy and safety of avatrombopag versus eltrombopag in ITP.
Topics: Benzoates; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic | 2023 |
Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Blood Platelets; Chronic Disease; Female; Humans; Hydrazines; Lymphoproliferative Disorders; Male; Middle Aged; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2019 |
Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study.
Topics: Adult; Benzoates; Female; Follow-Up Studies; Humans; Hydrazines; Pregnancy; Pregnancy Complications, Hematologic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Thrombopoietin | 2020 |
Treatment outcomes and chronicity predictors for primary immune thrombocytopenia: 10-year data from an academic center.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Benzoates; Child; Child, Preschool; Chronic Disease; Dexamethasone; Female; Humans; Hydrazines; Immunoglobulins, Intravenous; Infant; Infant, Newborn; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Retrospective Studies; Rituximab; Splenectomy | 2020 |
Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Cytokines; Drug Tapering; Female; Humans; Hydrazines; Lymphocytes; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Remission Induction; Withholding Treatment | 2021 |
Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia.
Topics: Aged; Aged, 80 and over; Benzoates; Female; Follow-Up Studies; Hemorrhage; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Thrombopoietin; Thrombosis | 2021 |
Phase 3 randomised trial of eltrombopag versus standard first-line pharmacological management for newly diagnosed immune thrombocytopaenia (ITP) in children: study protocol.
Topics: Benzoates; Child; Clinical Trials, Phase III as Topic; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice.
Topics: Aged; Benzoates; Chronic Disease; Follow-Up Studies; Humans; Hydrazines; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2017 |
Bone marrow characteristics predict outcome in a multicenter cohort of primary immune thrombocytopenia patients treated with thrombopoietin analogs.
Topics: Benzoates; Bone Marrow Cells; Female; Follow-Up Studies; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Retrospective Studies; Thrombopoietin | 2019 |
Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Blood Platelets; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Female; Hemorrhage; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Thrombopoietin | 2013 |
Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults.
Topics: Adult; Aged; Anti-Inflammatory Agents; Benzoates; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Feasibility Studies; Female; Follow-Up Studies; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Time Factors; Treatment Outcome | 2014 |
Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura.
Topics: Aged; Benzoates; Drug Resistance; Female; Humans; Hydrazines; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin | 2014 |
Use of eltrombopag after romiplostim in primary immune thrombocytopenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Thrombopoietin | 2015 |
Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study.
Topics: Adult; Benzoates; Bone Marrow; Bone Marrow Examination; Chronic Disease; Female; Follow-Up Studies; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Primary Myelofibrosis; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Reticulin | 2015 |
Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Topics: Adolescent; Benzoates; Child; Child, Preschool; Chronic Disease; Double-Blind Method; Female; Humans; Hydrazines; Infant; Male; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Treatment Outcome | 2015 |
Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
Topics: Adolescent; Benzoates; Canada; Child; Child, Preschool; Double-Blind Method; Female; France; Humans; Hydrazines; Infant; Male; Netherlands; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Spain; Treatment Outcome; United Kingdom; United States | 2015 |
Thrombopoietin receptor agonists shift the balance of Fcγ receptors toward inhibitory receptor IIb on monocytes in ITP.
Topics: Adult; Aged, 80 and over; Benzoates; Female; Humans; Hydrazines; Male; Middle Aged; Monocytes; Phagocytosis; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, IgG; Receptors, Thrombopoietin; Transforming Growth Factor beta1; Young Adult | 2016 |
A 2-Year, Longitudinal, Prospective Study of the Effects of Eltrombopag on Bone Marrow in Patients with Chronic Immune Thrombocytopenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Biopsy; Bone Marrow; Chronic Disease; Collagen; Female; Humans; Hydrazines; Male; Middle Aged; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Reticulin | 2017 |
Cytokine changes in response to TPO receptor agonist treatment in primary immune thrombocytopenia.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Cytokines; Female; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; RNA, Messenger; Th1 Cells; Th17 Cells; Thrombopoietin | 2017 |
Bidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Female; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2018 |
Bleeding tendency and platelet function during treatment with romiplostim in children with severe immune thrombocytopenic purpura.
Topics: Adolescent; Annexin A5; Antigens, CD; Benzoates; Blood Platelets; Child; Child, Preschool; Female; Hemorrhage; Humans; Hydrazines; Infant; Male; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I; Recombinant Fusion Proteins; Thrombopoietin | 2017 |
Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chronic Disease; Female; Hemorrhage; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Young Adult | 2009 |
Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Benzoates; Dose-Response Relationship, Drug; Female; Humans; Hydrazines; Male; Middle Aged; Models, Statistical; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Sex Characteristics; White People | 2011 |
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.
Topics: Adult; Benzoates; Chronic Disease; Double-Blind Method; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Splenectomy | 2011 |
Eltrombopag named patient programme for patients with chronic immune thrombocytopenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Child; Child, Preschool; Chronic Disease; Female; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2012 |
A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia.
Topics: Administration, Oral; Adult; Aged; Asian People; Benzoates; Blood Platelets; Chronic Disease; Double-Blind Method; Female; Hematologic Agents; Hemorrhage; Humans; Hydrazines; Japan; Male; Middle Aged; Placebos; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Time Factors; Treatment Outcome | 2012 |
Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Blood Platelets; Bone Marrow Diseases; Chronic Disease; Female; Hematologic Neoplasms; Hemorrhage; Humans; Hydrazines; Liver Diseases; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Treatment Outcome; Young Adult | 2013 |
Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP).
Topics: Adult; Aged; Benzoates; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Female; Hematinics; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Treatment Outcome; Young Adult | 2013 |
Function of eltrombopag-induced platelets compared to platelets from control patients with immune thrombocytopenia.
Topics: Adenosine Diphosphate; Adult; Austria; Benzoates; Blood Platelets; Collagen; Female; Humans; Hydrazines; Male; Middle Aged; Oligopeptides; P-Selectin; Platelet Activation; Platelet Adhesiveness; Platelet Function Tests; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Time Factors; Treatment Outcome; Young Adult | 2013 |
Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemorrhage; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Quality of Life; Receptors, Thrombopoietin; Recurrence; Thrombopoietin | 2007 |
198 other study(ies) available for hydrazine and Autoimmune Thrombocytopenia
| Article | Year |
|---|---|
Treatment of immune thrombocytopenia with eltrombopag in patients who had and who had not received prior rituximab: post-hoc analysis of the EXTEND study.
Topics: Benzoates; Clinical Trials, Phase III as Topic; Humans; Hydrazines; Molecular Targeted Therapy; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Retreatment; Rituximab; Treatment Outcome | 2022 |
Eltrombopag-induced Metabolic Acidosis and Hepatic Encephalopathy in Pediatric ITP.
Topics: Acidosis; Benzoates; Child; Child, Preschool; Hepatic Encephalopathy; Humans; Hydrazines; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2022 |
Eltrombopag treatment of patients with secondary immune thrombocytopenia: retrospective EHR analysis.
Topics: Adult; Aged; Benzoates; Female; Hemorrhage; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Thrombosis; Treatment Outcome | 2022 |
Eltrombopag treatment for severe immune thrombocytopenia during pregnancy: a case report.
Topics: Adolescent; Benzoates; Female; Humans; Hydrazines; Infant, Newborn; Platelet Count; Pregnancy; Pregnancy Complications, Hematologic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2021 |
Treatment patterns in adults with immune thrombocytopenia before, during and after use of thrombopoietin receptor agonists: a longitudinal prescription database study from Germany.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Databases, Factual; Drug Prescriptions; Female; Germany; Humans; Hydrazines; Longitudinal Studies; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Thrombopoietin | 2021 |
Spotlight on eltrombopag in pediatric ITP in China: a long-term observational study in real-world practice.
Topics: Benzoates; Child; Child, Preschool; China; Humans; Hydrazines; Longitudinal Studies; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Thrombocytopenia; Treatment Outcome | 2021 |
Efficiency and safety of eltrombopag for multi-line failed Chinese patients with immune thrombocytopenia: cases with decreased megakaryocyte response well from single-center experience.
Topics: Benzoates; China; Humans; Hydrazines; Megakaryocytes; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Retrospective Studies; Thrombocytopenia | 2022 |
Eltrombopag-associated erythromelalgia in idiopathic thrombocytopenic purpura.
Topics: Benzoates; Erythromelalgia; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2022 |
Eltrombopag as second line treatment in patients with primary immune thrombocytopenia: A single center real life experience.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Female; Glucocorticoids; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Treatment Outcome; Young Adult | 2021 |
Eltrombopag in adult patients with immune thrombocytopenia in the real-world in France, including off-label use before 6 months of disease duration: The multicenter, prospective ELEXTRA study.
Topics: Adult; Aged; Benzoates; Female; France; Humans; Hydrazines; Male; Middle Aged; Off-Label Use; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Treatment Outcome | 2022 |
Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia.
Topics: Benzoates; Canada; Cost-Benefit Analysis; Humans; Hydrazines; Immunoglobulins, Intravenous; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Thrombocytopenia | 2022 |
Eltrombopag for refractory vaccine-induced immune thrombotic thrombocytopenia.
Topics: Antibodies; Benzoates; COVID-19; COVID-19 Vaccines; Female; Humans; Hydrazines; Middle Aged; Platelet Factor 4; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Thrombocytopenia; Thrombosis; Vaccines | 2022 |
Catastrophic anti-phospholipid syndrome with Libman-Sacks endocarditis following eltrombopag therapy for immune thrombocytopenic purpura: A case report.
Topics: Adult; Antiphospholipid Syndrome; Benzoates; Endocarditis; Female; Humans; Hydrazines; Lupus Erythematosus, Systemic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2021 |
Chronic Myeloid Leukemia in a Patient with Previous Idiopathic Thrombocytopenic Purpura: How to Manage Imatinib Together with Eltrombopag.
Topics: Benzoates; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2021 |
Eltrombopag in paediatric immune thrombocytopenia: Iron metabolism modulation in mesenchymal stromal cells.
Topics: Anti-Inflammatory Agents; Benzoates; Child; Humans; Hydrazines; Iron; Mesenchymal Stem Cells; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Thrombocytopenia | 2022 |
Early treatment of rituximab combined with eltrombopag for secondary thrombocytopenic purpura in rheumatoid arthritis: A case report.
Topics: Aged; Arthritis, Rheumatoid; Benzoates; Female; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Rituximab | 2022 |
Effects of eltrombopag on mesenchymal stem cells in immune thrombocytopenia purpura.
Topics: Benzoates; Humans; Hydrazines; Mesenchymal Stem Cells; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2022 |
Treatment patterns of thrombopoietin receptor agonists among adults with primary immune thrombocytopenia: A Korean nationwide population-based study.
Topics: Adult; Benzoates; Child, Preschool; Female; Humans; Hydrazines; Infant; Infant, Newborn; Male; Purpura, Thrombocytopenic, Idiopathic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Splenectomy; Thrombocytopenia; Thrombopoietin | 2022 |
Tapering of the thrombopoietin receptor agonist in paediatric patients with chronic immune thrombocytopenia: Is it possible?
Topics: Benzoates; Blood Platelets; Child; Hematologic Agents; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2022 |
Regulatory T cells are replenished in the splenic microenvironment of patients with immune thrombocytopenia by treatment with thrombopoietin receptor agonists.
Topics: Benzoates; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; T-Lymphocytes, Regulatory; Thrombocytopenia; Thrombopoietin | 2022 |
Thrombopoietin receptor agonists in adult Evans syndrome: an international multicenter experience.
Topics: Adult; Anemia, Hemolytic, Autoimmune; Benzoates; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2022 |
Thrombopoietin receptor agonist discontinuation rates and reasons among patients with immune thrombocytopenia: a study of administrative claims linked with medical chart review.
Topics: Adult; Aged; Benzoates; Hematologic Agents; Humans; Hydrazines; Medicare; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Thrombopoietin; United States | 2022 |
Eltrombopag in patients with chronic immune thrombocytopenia in Asia-Pacific, the Middle East, and Turkey: final analysis of CITE.
Topics: Adult; Asia; Chronic Disease; Humans; Hydrazines; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Quality of Life; Turkey | 2023 |
Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: A Canadian retrospective cohort study.
Topics: Adult; Canada; Chronic Disease; Hemorrhage; Humans; Hydrazines; Intracranial Hemorrhages; Purpura, Thrombocytopenic, Idiopathic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Rituximab; Thrombocytopenia; Thrombopoietin | 2022 |
Eltrombopag modulates the phenotypic evolution and potential immunomodulatory roles of monocytes/macrophages in immune thrombocytopenia.
Topics: Benzoates; Humans; Hydrazines; Interleukin-4; Macrophages; Monocytes; Phenotype; Purpura, Thrombocytopenic, Idiopathic; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2023 |
Evaluating the impact of thrombopoietin receptor agonist medications on patient outcomes and quality of life in paediatric immune thrombocytopenia through semi-structured interviews.
Topics: Child; Hematologic Agents; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Quality of Life; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Thrombocytopenia; Thrombopoietin | 2023 |
Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study.
Topics: Adult; Benzoates; Drug Substitution; Humans; Hydrazines; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Recombinant Proteins; Thrombocytopenia; Thrombopoietin | 2022 |
Evaluation of the procoagulant state in chronic immune thrombocytopenia before and after eltrombopag treatment-a prospective cohort study.
Topics: Adult; Factor VIII; Humans; Hydrazines; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Thrombin; Thrombocytopenia; Thrombophilia; von Willebrand Factor | 2023 |
Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study.
Topics: Adult; Autoimmunity; Humans; Hydrazines; Middle Aged; Platelet Count; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2023 |
Sustained response off treatment in eltrombopag for children with persistent/chronic primary immune thrombocytopenia: A multicentre observational retrospective study in China.
Topics: Adult; Benzoates; Child; China; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Receptors, Thrombopoietin; Retrospective Studies; Treatment Outcome | 2023 |
Pediatric immune thrombocytopenia: a focus on eltrombopag as second-line therapy.
Topics: Adult; Benzoates; Child; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia | 2023 |
Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in The Netherlands (TRAPeze Netherlands study).
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Female; Humans; Hydrazines; Male; Middle Aged; Netherlands; Patient Preference; Purpura, Thrombocytopenic, Idiopathic; Quality of Life; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin; Young Adult | 2023 |
Analysis of clinical characteristics and treatment efficacy in two pediatric cases of
Topics: Benzoates; Humans; Hydrazines; Infant; Intercellular Signaling Peptides and Proteins; Mutation; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia; Treatment Outcome | 2023 |
Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Female; Follow-Up Studies; Humans; Hydrazines; Male; Middle Aged; Prognosis; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Survival Rate; Thrombopoietin; Young Adult | 2019 |
Cutaneous thrombosis associated with eltrombopag treatment for immune thrombocytopenia.
Topics: Aged; Benzoates; Biopsy; Clopidogrel; Computed Tomography Angiography; Conservative Treatment; Female; Humans; Hydrazines; Hyperbaric Oxygenation; Ischemia; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Skin; Thrombosis; Tibial Arteries; Toes; Treatment Outcome; Warfarin | 2020 |
Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia.
Topics: Age Factors; Aged; Aged, 80 and over; Benzoates; Biomarkers; Combined Modality Therapy; Comorbidity; Drug Therapy, Combination; Female; Humans; Hydrazines; Male; Prognosis; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Retrospective Studies; Treatment Outcome | 2020 |
A Sticky Situation: Aortic Valve Thrombus in Patient with Antiphospholipid Antibody Syndrome and Immune Thrombocytopenia.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aortic Valve; Aortic Valve Stenosis; Benzoates; Bicuspid Aortic Valve Disease; Bioprosthesis; Chest Pain; Craniotomy; Echocardiography; Echocardiography, Three-Dimensional; Echocardiography, Transesophageal; Enoxaparin; Female; Heart Valve Diseases; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Hematoma, Subdural, Acute; Humans; Hydrazines; Immunologic Factors; Plasma Exchange; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Recurrence; Rituximab; Stroke Volume; Thrombosis; Ventricular Dysfunction, Left; Warfarin | 2020 |
No increased risk of cataract in adult patients with primary immune thrombocytopenia treated with eltrombopag. A French nationwide nested case-control study.
Topics: Aged; Aged, 80 and over; Benzoates; Case-Control Studies; Cataract; Female; France; Humans; Hydrazines; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2020 |
Real-world evidence on clinical outcomes in immune thrombocytopenia treated with thrombopoietin receptor agonists.
Topics: Adult; Aged; Benzoates; Cross-Sectional Studies; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Thrombopoietin | 2020 |
Outcomes of Eltrombopag Treatment and Development of Iron Deficiency in Children with Immune Thrombocytopenia in Turkey
Topics: Administration, Oral; Adolescent; Anemia, Iron-Deficiency; Benzoates; Child; Child, Preschool; Female; Humans; Hydrazines; Infant; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Retrospective Studies; Treatment Outcome; Turkey | 2020 |
The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.
Topics: Benzoates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Hemorrhage; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; United States | 2020 |
"ITP" is not always immune thrombocytopenia.
Topics: Adrenal Cortex Hormones; Amino Acid Substitution; Benzoates; Bernard-Soulier Syndrome; Child; Diagnosis, Differential; Humans; Hydrazines; Immunoglobulins, Intravenous; Male; Mutation, Missense; Platelet Glycoprotein GPIb-IX Complex; Platelet Transfusion; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin | 2020 |
Efficacy and safety of eltrombopag during conception and first trimester of pregnancy in a case of refractory severe immune thrombocytopenia.
Topics: Adolescent; Benzoates; Female; Humans; Hydrazines; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Trimester, First; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Treatment Outcome | 2020 |
Preparing patients with immune thrombocytopenia for surgery: what are the options?
Topics: Benzoates; Humans; Hydrazines; Immunoglobulins, Intravenous; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Thrombocytopenia | 2020 |
Cost-per-responder analysis for eltrombopag and rituximab in the treatment of primary immune thrombocytopenia in Spain.
Topics: Adult; Benzoates; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Rituximab; Spain; Thrombopoietin | 2020 |
A simple HPLC assay for determining eltrombopag concentration in human serum.
Topics: Benzoates; Chromatography, High Pressure Liquid; Diclofenac; Drug Monitoring; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Reference Standards | 2021 |
Efficacy and safety of eltrombopag in the treatment of Chinese children with chronic immune thrombocytopenia.
Topics: Benzoates; Child; Child, Preschool; China; Chronic Disease; Female; Humans; Hydrazines; Infant; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; T-Lymphocytes, Regulatory; Treatment Outcome | 2021 |
Effects of Eltrombopag on In Vitro Macrophage Polarization in Pediatric Immune Thrombocytopenia.
Topics: B-Lymphocytes, Regulatory; Benzoates; Child; Child, Preschool; Female; Humans; Hydrazines; Macrophage Activation; Macrophages; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; T-Lymphocytes, Regulatory; Th1 Cells; Th2 Cells | 2020 |
Thrombopoietin receptor agonists as an emergency treatment for severe newly diagnosed immune thrombocytopenia in children.
Topics: Adolescent; Benzoates; Child; Child, Preschool; Emergency Treatment; Female; Hemorrhage; Humans; Hydrazines; Infant; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2021 |
An escalating treatment strategy for children with severe chronic immune thrombocytopenia: Preliminary report from a single center.
Topics: Adolescent; Anti-Inflammatory Agents; Benzoates; Child; Child, Preschool; Dexamethasone; Drug Therapy, Combination; Female; Humans; Hydrazines; Immunologic Factors; Infant; Male; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Rituximab; Treatment Outcome | 2021 |
Eltrombopag for the treatment of refractory thrombocytopenia associated with connective tissue disease.
Topics: Adult; Benzoates; Connective Tissue Diseases; Female; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Young Adult | 2021 |
Eltrombopag-induced recurrent stroke in idiopathic thrombocytopenic purpura.
Topics: Benzoates; Humans; Hydrazines; Purpura, Thrombocytopenic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Stroke | 2021 |
Tapering and Discontinuation of Thrombopoietin Receptor Agonist Therapy in Patients with Immune Thrombocytopenia: Results from a Modified Delphi Panel.
Topics: Benzoates; Humans; Hydrazines; Medication Adherence; Physicians; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Recurrence; Remission Induction; Retreatment; Self Report; Surveys and Questionnaires; Thrombopoietin | 2021 |
Acute kidney injury and nephrotic syndrome associated with eltrombopag therapy in chronic idiopathic thrombocytopenic purpura.
Topics: Acute Kidney Injury; Adrenal Cortex Hormones; Aged; Benzoates; Humans; Hydrazines; Kidney; Male; Nephrotic Syndrome; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2021 |
Management of primary immune thrombocytopenia in a real-world setting in Japan: eltrombopag versus corticosteroids.
Topics: Adrenal Cortex Hormones; Benzoates; Disease Management; Disease Susceptibility; Drug Therapy, Combination; Hemorrhage; Humans; Hydrazines; Japan; Kaplan-Meier Estimate; Patient Acceptance of Health Care; Platelet Count; Practice Patterns, Physicians'; Prevalence; Prognosis; Proportional Hazards Models; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Retrospective Studies; Treatment Outcome | 2021 |
Immune thrombocytopenia in two infant cases managed with eltrombopag.
Topics: Benzoates; Humans; Hydrazines; Infant; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Thrombocytopenia; Treatment Outcome | 2021 |
Could Antinuclear Antibody Positivity Be a Factor Affecting Treatment Response in Immune Thrombocytopenia Patients on Eltrombopag?
Topics: Antibodies, Antinuclear; Benzoates; Female; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Treatment Outcome | 2022 |
Comparison of Splenectomy and Eltrombopag Treatment in the Second-Line Treatment of Immune Thrombocytopenic Purpura
Topics: Adult; Benzoates; Humans; Hydrazines; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Retrospective Studies; Splenectomy | 2021 |
Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico Approach.
Topics: Benzoates; Biomarkers; Disease Management; Disease Susceptibility; Humans; Hydrazines; Immunomodulation; Models, Biological; Models, Molecular; Molecular Targeted Therapy; Protein Interaction Mapping; Protein Interaction Maps; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Signal Transduction; Structure-Activity Relationship; T-Lymphocytes; Treatment Outcome | 2021 |
Eltrombopag-induced liver dysfunction during the treatment of immune thrombocytopenia and its risk factors.
Topics: Benzoates; Diabetes Mellitus, Type 2; Female; Humans; Hydrazines; Liver Diseases; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Risk Factors | 2021 |
Use of eltrombopag for secondary immune thrombocytopenia in clinical practice.
Topics: Adult; Aged; Autoimmune Diseases; Benzoates; Drug Administration Schedule; Female; Humans; Hydrazines; Lymphoproliferative Disorders; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Virus Diseases | 2017 |
Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Drug Substitution; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Time Factors; Treatment Outcome; Young Adult | 2017 |
Comparative treatment-related adverse event cost burden in immune thrombocytopenic purpura.
Topics: Adult; Aged; Benzoates; Female; Humans; Hydrazines; Immunoglobulins, Intravenous; Immunologic Factors; Insurance Claim Review; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Retrospective Studies; Rho(D) Immune Globulin; Rituximab; Thrombopoietin | 2017 |
Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Benzoates; Decitabine; Dioxygenases; DNA-Binding Proteins; Drug Monitoring; Female; Hematologic Agents; Humans; Hydrazines; Leukemia, Myelomonocytic, Chronic; Middle Aged; Mutation; Nuclear Proteins; Platelet Count; Proto-Oncogene Proteins; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Ribonucleoproteins; Serine-Arginine Splicing Factors; Thrombocytopenia; Thrombopoietin; Treatment Outcome | 2017 |
A sticky situation: myocardial infarction in a young woman with immune thrombocytopenia on eltrombopag and a history of mediastinal radiation.
Topics: Benzoates; Female; Humans; Hydrazines; Mediastinal Neoplasms; Myocardial Infarction; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Risk Factors; Splenectomy; Young Adult | 2018 |
[Novelties in the treatment of pediatric immune thrombocytopenia - 2017].
Topics: Adolescent; Benzoates; Child; Child, Preschool; Drug Resistance; Humans; Hydrazines; Immunoglobulins, Intravenous; Infant; Infant, Newborn; Medication Therapy Management; Pediatrics; Prognosis; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Splenectomy; Steroids | 2017 |
Thrombopoietin receptor agonists in patients with persistent or chronic immune thrombocytopenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Blood Platelets; Child; Child, Preschool; Chronic Disease; Female; Gene Expression Regulation; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Splenectomy; Thrombopoietin; Time-to-Treatment; Treatment Outcome | 2018 |
Eltrombopag, low-dose rituximab, and dexamethasone combination as frontline treatment of newly diagnosed immune thrombocytopaenia.
Topics: Adolescent; Adult; Benzoates; Dexamethasone; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Rituximab | 2019 |
Eltrombopag with i.v. immunoglobulin for safe splenectomy in refractory immune thrombocytopenia.
Topics: Benzoates; Child, Preschool; Combined Modality Therapy; Drug Therapy, Combination; Female; Humans; Hydrazines; Immunoglobulins, Intravenous; Immunologic Factors; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Splenectomy | 2018 |
Thrombosis of a Left Atrial Appendage Occluder After Treatment With Thrombopoietin Receptor Agonists.
Topics: Aged; Atrial Appendage; Atrial Fibrillation; Benzoates; Cardiac Catheterization; Device Removal; Echocardiography, Three-Dimensional; Hematologic Agents; Humans; Hydrazines; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Risk Factors; Thrombectomy; Thrombosis; Treatment Outcome | 2018 |
Modeling and Simulation Support Eltrombopag Dosing in Pediatric Patients With Immune Thrombocytopenia.
Topics: Adolescent; Age Factors; Benzoates; Blood Platelets; Child; Child, Preschool; Computer Simulation; Drug Dosage Calculations; Female; Hematinics; Humans; Hydrazines; Infant; Male; Models, Biological; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Treatment Outcome | 2018 |
Safety and efficacy of thrombopoeitin mimetics for refractory immune thrombocytopenia purpura in patients with systemic lupus erythematosus or antiphospholipid syndrome: a case series.
Topics: Antiphospholipid Syndrome; Autoimmunity; Benzoates; Blood Platelets; Female; Hemorrhage; Humans; Hydrazines; Lupus Erythematosus, Systemic; Middle Aged; Molecular Mimicry; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombin; Recombinant Fusion Proteins; Retrospective Studies; Risk Factors; Thrombopoietin; Treatment Outcome; Virginia; Young Adult | 2018 |
Treatment characteristics, efficacy and safety of thrombopoietin analogues in routine management of primary immune thrombocytopenia.
Topics: Adult; Aged; Benzoates; Disease Management; Female; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Thrombopoietin; Treatment Outcome | 2018 |
A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonists.
Topics: Benzoates; Chronic Disease; Clinical Decision-Making; Cost-Benefit Analysis; Costs and Cost Analysis; Decision Support Techniques; Drug Costs; Hemorrhage; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; United States | 2018 |
Efficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia: Results from a long-term observation in clinical practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Benzoates; Child; Child, Preschool; Combined Modality Therapy; Cyclosporine; Dapsone; Dexamethasone; Drug Resistance; Drug Therapy, Combination; Female; Humans; Hydrazines; Immunoglobulins, Intravenous; Immunosuppressive Agents; Male; Middle Aged; Prednisolone; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Remission Induction; Retrospective Studies; Rho(D) Immune Globulin; Rituximab; Splenectomy; Thrombopoietin; Treatment Outcome; Young Adult | 2018 |
Immune Thrombocytopenia in a Child With Refractory Langerhans Cell Histiocytosis Following Cladribine Containing Therapy.
Topics: Benzoates; Cladribine; Dexamethasone; Female; Histiocytosis, Langerhans-Cell; Humans; Hydrazines; Immunoglobulins, Intravenous; Infant; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2019 |
Thrombopoietin mimetics for systemic lupus erythematosus with antiphospholipid antibodies should be discussed separately.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Benzoates; Humans; Hydrazines; Lupus Erythematosus, Systemic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin; Venous Thromboembolism | 2018 |
Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia.
Topics: Benzoates; Dose-Response Relationship, Drug; Female; Hematologic Agents; Humans; Hydrazines; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thiazoles; Thiophenes; Thrombopoietin; Treatment Outcome | 2018 |
Severe immune thrombocytopenia in pregnancy treated with Eltrombopag - A case report.
Topics: Adult; Benzoates; Female; Humans; Hydrazines; Live Birth; Pregnancy; Pregnancy Complications, Hematologic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2018 |
Cost per response analysis of strategies for chronic immune thrombocytopenia.
Topics: Adult; Bayes Theorem; Benzoates; Cost-Benefit Analysis; Decision Trees; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Costs; Female; Humans; Hydrazines; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin; Treatment Failure; Treatment Outcome | 2018 |
An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Benzoates; Drug Administration Schedule; Female; Hemorrhage; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Quality of Life; Receptors, Thrombopoietin; Retrospective Studies; Treatment Outcome; Young Adult | 2018 |
Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia.
Topics: Benzoates; Female; Humans; Hydrazines; Logistic Models; Male; Predictive Value of Tests; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Thrombopoietin | 2018 |
Health-related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study.
Topics: Adolescent; Benzoates; Child; Child, Preschool; Female; Humans; Hydrazines; Infant; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Quality of Life; Thrombopoietin; Treatment Outcome | 2019 |
Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
Topics: Benzoates; Blood Platelets; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Treatment Outcome | 2018 |
Thrombopoietin receptor agonist switch in children with persistent and chronic severe immune thrombocytopenia: A retrospective analysis in a large tertiary center.
Topics: Adolescent; Benzoates; Child; Child, Preschool; Chronic Disease; Female; Follow-Up Studies; Humans; Hydrazines; Male; Platelet Count; Prognosis; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Severity of Illness Index; Tertiary Care Centers; Thrombopoietin | 2019 |
Glucocorticoids promote response to thrombopoietin-receptor agonists in refractory ITP: a case series.
Topics: Adolescent; Adult; Aged; Benzoates; Child, Preschool; Combined Modality Therapy; Drug Synergism; Drug Therapy, Combination; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Prednisone; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Splenectomy; Thrombopoietin | 2019 |
Eltrombopag: Efficacy and Safety in Steroid Refractory Lupus-Associated Immune Thrombocytopenia.
Topics: Benzoates; Humans; Hydrazines; Lupus Erythematosus, Systemic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Steroids | 2020 |
Thrombopoietin receptor agonists as second-line therapy in splenectomy-eligible persistent immune thrombocytopenia: a case series.
Topics: Adrenal Cortex Hormones; Benzoates; Chronic Disease; Drug Resistance; Female; Humans; Hydrazines; Immunoglobulins, Intravenous; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Splenectomy; Thrombopoietin | 2019 |
Blood transcriptome and clonal T-cell correlates of response and non-response to eltrombopag therapy in a cohort of patients with chronic immune thrombocytopenia.
Topics: Benzoates; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; T-Lymphocytes; Transcriptome | 2020 |
Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma.
Topics: Adult; Aged; Benzoates; Female; Humans; Hydrazines; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm Proteins; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2019 |
No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura.
Topics: Benzoates; Chronic Disease; Drug Resistance; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Salvage Therapy; Thrombopoietin; Treatment Outcome | 2013 |
A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Drug Substitution; Female; Humans; Hydrazines; Male; Middle Aged; Pilot Projects; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Thrombopoietin; Treatment Outcome | 2013 |
Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists.
Topics: Adult; Autoantibodies; Benzoates; Blood Platelets; Chronic Disease; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2013 |
Refractory idiopathic thrombocytopenic purpura treated with immunoadsorption using tryptophan column.
Topics: Adsorption; Adult; Benzoates; Blood Component Removal; Ecchymosis; Humans; Hydrazines; Immunologic Techniques; Immunosuppressive Agents; Male; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Remission Induction; Splenectomy; Steroids; Treatment Outcome | 2013 |
Retrospective analysis of eltrombopag for the treatment of refractory primary immune thrombocytopenia in Japan.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Benzoates; Female; Humans; Hydrazines; Japan; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Treatment Outcome | 2013 |
Idiopathic thrombocytopenic purpura resistant to eltrombopag, but cured with romiplostim.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Anticonvulsants; Benzoates; Drug Interactions; Drug Resistance; Humans; Hydrazines; Immunoglobulins, Intravenous; Male; Prednisone; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Recurrence; Rituximab; Thrombopoietin | 2014 |
Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
Topics: Benzoates; Drug Resistance; Drug Substitution; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Treatment Outcome | 2013 |
Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists.
Topics: Adult; Aged; Antiphospholipid Syndrome; Benzoates; Bone Marrow Diseases; Drug Evaluation; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hydrazines; Male; Middle Aged; Patient Selection; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Salvage Therapy; Thrombocytopenia; Thrombopoiesis; Thrombopoietin | 2013 |
Sudden blindness due to bilateral central retinal artery occlusion in a patient on eltrombopag.
Topics: Benzoates; Blindness; Female; Fibrinolytic Agents; Humans; Hydrazines; Methylprednisolone; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Recovery of Function; Retinal Artery Occlusion | 2014 |
Immune thrombocytopenia successfully treated with eltrombopag following multiple therapies including romiplostim.
Topics: Benzoates; Humans; Hydrazines; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin | 2014 |
Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag.
Topics: Benzoates; Chronic Disease; Dentistry, Operative; Hemorrhage; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Treatment Outcome | 2015 |
Update on romiplostim and eltrombopag indirect comparison.
Topics: Benzoates; Female; Humans; Hydrazines; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin | 2014 |
Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia.
Topics: Adult; Aged; Benzoates; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Treatment Outcome | 2015 |
Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia.
Topics: Adult; Aged; Apoptosis; Autoantibodies; Benzoates; Blood Coagulation; Blood Platelets; Cell-Derived Microparticles; Female; Humans; Hydrazines; Male; Middle Aged; Plasma; Platelet Activation; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2014 |
Eltrombopag therapy in newly diagnosed steroid non-responsive ITP patients.
Topics: Adolescent; Adult; Benzoates; Drug Resistance; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Steroids; Time Factors; Treatment Outcome; Young Adult | 2014 |
Effect of thrombopoietin-receptor agonists on a proliferation-inducing ligand (APRIL) plasma levels in patients with immune thrombocytopaenia.
Topics: Aged; Benzoates; Case-Control Studies; Female; Humans; Hydrazines; Immunoglobulins, Intravenous; Male; Middle Aged; Myelodysplastic Syndromes; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Tumor Necrosis Factor Ligand Superfamily Member 13 | 2014 |
The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Drug Therapy, Combination; Female; France; Humans; Hydrazines; Immunologic Factors; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Splenectomy; Thrombopoietin; Treatment Outcome; Young Adult | 2014 |
[Effectiveness of perioperative administration of eltrombopag in a patient with idiopathic thrombocytopenic purpura undergoing cardiovascular surgery].
Topics: Aged; Aortic Aneurysm; Aortic Dissection; Benzoates; Coronary Artery Bypass; Coronary Disease; Humans; Hydrazines; Male; Perioperative Period; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Thrombopoietin | 2014 |
Thrombopoietin receptor agonists in immune thrombocytopenia of less than 6 months duration.
Topics: Aged; Benzoates; Drug Evaluation; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Hydrazines; Immunosuppressive Agents; Male; Middle Aged; Platelet Count; Prednisolone; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Time Factors | 2014 |
Thrombopoietic agents for the treatment of persistent and chronic immune thrombocytopenia in children.
Topics: Adolescent; Benzoates; Child; Child, Preschool; Chronic Disease; Female; Humans; Hydrazines; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Retrospective Studies; Thrombopoietin; Young Adult | 2014 |
Immune thrombocytopenia during childhood: new approaches to classification and management.
Topics: Benzoates; Female; Humans; Hydrazines; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin | 2014 |
Platelet fluctuations during thrombopoietin-receptor agonist treatment: correlation with platelet apoptosis.
Topics: Adult; Apoptosis; Benzoates; Blood Platelets; Female; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Time Factors | 2015 |
Eltrombopag for resistant immune thrombocytopenia secondary to chronic lymphocytic leukaemia.
Topics: Benzoates; Humans; Hydrazines; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2014 |
Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia.
Topics: Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Benzoates; Blood Platelets; Case-Control Studies; Chronic Disease; Gene Expression Regulation; Humans; Hydrazines; Megakaryocytes; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Signal Transduction; Thrombopoietin | 2014 |
Is there a role for low-dose eltrombopag as maintenance therapy in the treatment of immune thrombocytopenia?
Topics: Adult; Aged; Benzoates; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Treatment Outcome | 2015 |
Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus.
Topics: Adult; Aged; Benzoates; Female; Humans; Hydrazines; Lupus Erythematosus, Systemic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Treatment Outcome | 2014 |
Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.
Topics: Adult; Aged; Benzoates; Blood Platelets; Chronic Disease; Drug Administration Schedule; Drug Monitoring; Erythropoiesis; Female; Follow-Up Studies; Hematinics; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Recurrence; Remission Induction; Retrospective Studies; Splenectomy; Treatment Outcome | 2015 |
Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Adult; Benzoates; Female; Humans; Hydrazines; Lupus Erythematosus, Systemic; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Thrombopoietin | 2015 |
Successful eltrombopag treatment of refractory idiopathic thrombocytopenic purpura associated with Crohn disease.
Topics: Adult; Benzoates; Crohn Disease; Female; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Remission Induction | 2015 |
Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
Topics: Benzoates; Chronic Disease; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Treatment Outcome | 2015 |
Successful management of refractory immune thrombocytopenia associated with massive alveolar hemorrhage.
Topics: Adult; Benzoates; Factor VIIa; Hemorrhage; Humans; Hydrazines; Immunosuppressive Agents; Male; Platelet Count; Prednisone; Pulmonary Alveoli; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Radiography, Thoracic; Skull; Tomography, X-Ray Computed; Vincristine | 2015 |
Are risk evaluation and mitigation strategies associated with less off-label use of medications? The case of immune thrombocytopenia.
Topics: Adolescent; Adult; Aged; Benzoates; Female; Hepatitis C; Humans; Hydrazines; Male; Middle Aged; Off-Label Use; Patient Safety; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Retrospective Studies; Risk Assessment; Risk Reduction Behavior; Thrombopoietin; United States; Young Adult | 2015 |
[Development of chronic myelogenous leukemia during treatment with TPO receptor agonist for ITP].
Topics: Aged; Benzoates; Biopsy; Bone Marrow; Fatal Outcome; Humans; Hydrazines; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2014 |
Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience.
Topics: Adrenal Cortex Hormones; Adult; Benzoates; Combined Modality Therapy; Drug Evaluation; Drug Resistance; Female; Hemorrhage; Humans; Hydrazines; Male; Middle Aged; Myocardial Infarction; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Sinus Thrombosis, Intracranial; Splenectomy; Turkey | 2015 |
Population Pharmacokinetic and Pharmacodynamic Modeling and Effects on Platelet Counts of Different Dosages of Eltrombopag in Chinese Patients With Chronic Primary Immune Thrombocytopenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Benzoates; Blood Platelets; China; Female; Humans; Hydrazines; Male; Middle Aged; Models, Theoretical; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Young Adult | 2015 |
Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP.
Topics: Benzoates; Child; Female; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Treatment Outcome | 2015 |
Thrombopoietin-receptor agonists in children with immune thrombocytopenia.
Topics: Benzoates; Female; Humans; Hydrazines; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2015 |
Efficacy and safety of eltrombopag in treatment-refractory primary immune thrombocytopenia: a retrospective study.
Topics: Adult; Benzoates; Female; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Retrospective Studies; Treatment Outcome | 2016 |
Eltrombopag in systemic lupus erythematosus with antiphospholipid syndrome: thrombotic events.
Topics: Benzoates; Female; Humans; Hydrazines; Lupus Erythematosus, Systemic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2016 |
Is there still a place for "old therapies" in the management of immune thrombocytopenia?
Topics: Benzoates; Danazol; Dapsone; Humans; Hydrazines; Hydroxychloroquine; Immunoglobulins, Intravenous; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thrombopoietin; Vinca Alkaloids | 2016 |
Eltrombopag enhances platelet adhesion by upregulating the expression of glycoprotein VI in patients with chronic immune thrombocytopenic purpura.
Topics: Adult; Aged; Benzoates; Blood Platelets; Cell Adhesion; Chronic Disease; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Membrane Glycoproteins; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Up-Regulation; Young Adult | 2015 |
Age and Bone Marrow Cellularity are Associated with Response to Eltrombopag in Japanese Adult Immune Thrombocytopenia Patients: A Retrospective Single-Center Study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Asian People; Benzoates; Bone Marrow Cells; Female; Hematopoietic Stem Cells; Humans; Hydrazines; Male; Middle Aged; Pluripotent Stem Cells; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Retrospective Studies; Treatment Outcome; Young Adult | 2015 |
The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
Topics: Aged; Benzoates; Cohort Studies; Female; Hospitals; Humans; Hydrazines; Italy; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Thrombopoietin | 2016 |
Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice.
Topics: Aged; Benzoates; Chronic Disease; Female; Humans; Hydrazines; Immunosuppressive Agents; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Retreatment; Retrospective Studies; Spain; Treatment Outcome | 2016 |
Eltrombopag for chronic immune thrombocytopenia - Authors' reply.
Topics: Benzoates; Female; Humans; Hydrazines; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2016 |
Eltrombopag for chronic immune thrombocytopenia.
Topics: Benzoates; Female; Humans; Hydrazines; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2016 |
Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Benzoates; Combined Modality Therapy; Drug Resistance; Female; Humans; Hydrazines; Immunoglobulins, Intravenous; Italy; Male; Middle Aged; Platelet Count; Portal Vein; Postoperative Complications; Premedication; Preoperative Care; Pulmonary Embolism; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Salvage Therapy; Splenectomy; Thrombophilia; Thrombopoiesis; Thrombopoietin; Venous Thrombosis; Young Adult | 2016 |
Spontaneous regression of adult T cell leukemia/lymphoma following development of immune thrombocytopenia.
Topics: Adrenal Cortex Hormones; Allografts; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Leukemia-Lymphoma, Adult T-Cell; Middle Aged; Nitrosourea Compounds; Prednisolone; Prednisone; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Remission, Spontaneous; Vincristine; Vindesine | 2016 |
Use of Thrombopoietin-Receptor Agonist in CVID-Associated Immune Thrombocytopenia.
Topics: Adult; Benzoates; Common Variable Immunodeficiency; Female; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2016 |
Immune Thrombocytopenia Resolved by Eltrombopag in a Carrier of Glucose-6-Phosphate Dehydrogenase Deficiency.
Topics: Benzoates; Blood Platelets; Elective Surgical Procedures; Female; Glycogen Storage Disease Type I; Hemolysis; Heterozygote; Humans; Hydrazines; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Splenectomy | 2016 |
Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study.
Topics: Adolescent; Benzoates; Child; Female; Humans; Hydrazines; Male; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Thrombopoietin | 2016 |
Development of myelofibrosis during eltrombopag treatment in a patient with immune thrombocytopenia.
Topics: Aged; Benzoates; Biopsy; Humans; Hydrazines; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Treatment Outcome | 2016 |
Cytomegalovirus-associated thrombocytopenia treated with thrombopoietin receptor agonist.
Topics: Antiviral Agents; Benzoates; Cytomegalovirus; Cytomegalovirus Infections; Female; Humans; Hydrazines; Middle Aged; Prednisone; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2016 |
Management of Primary Immune Thrombocytopenia With Eltrombopag in a Patient With Recent Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Benzoates; Electrocardiography; Humans; Hydrazines; Male; Middle Aged; Percutaneous Coronary Intervention; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Splenectomy | 2017 |
Eltrombopag (thrombopoietin-receptor agonist) and plasmapheresis as rescue therapy of acute post-renal transplant immune thrombocytopenia in a child with Schimke immuno-osseous dysplasia-case report.
Topics: Arteriosclerosis; Benzoates; Child; DNA Helicases; Humans; Hydrazines; Immunologic Deficiency Syndromes; Kidney Transplantation; Male; Mutation; Nephrotic Syndrome; Osteochondrodysplasias; Plasmapheresis; Platelet Count; Primary Immunodeficiency Diseases; Pulmonary Embolism; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Thrombopoietin; Time Factors | 2016 |
[Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study].
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Female; France; Humans; Hydrazines; Male; Middle Aged; Pharmacovigilance; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Thrombopoietin; Thrombosis; Young Adult | 2017 |
Acute Myocardial Infarction Due to Eltrombopag Therapy in a Patient with Immune Thrombocytopenic Purpura.
Topics: Acute Disease; Benzoates; Humans; Hydrazines; Male; Middle Aged; Myocardial Infarction; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2017 |
Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center.
Topics: Benzoates; Female; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Treatment Outcome | 2017 |
Therapy induced iron deficiency in children treated with eltrombopag for immune thrombocytopenia.
Topics: Adolescent; Anemia, Iron-Deficiency; Benzoates; Drug Therapy, Combination; Female; Ferritins; Humans; Hydrazines; Iron; Iron Chelating Agents; Male; Molecular Structure; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin; Young Adult | 2017 |
Thrombopoetin receptor agonist therapy in thrombocytopenia: ITP and beyond.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; Thrombocytopenia; Treatment Outcome; Young Adult | 2017 |
Boosting platelet production.
Topics: Benzoates; Blood Platelets; Humans; Hydrazines; Models, Immunological; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2008 |
[Thrombopoietin-receptor agonists: a revolution in the therapeutic strategies of immune thrombocytopenic purpura?].
Topics: Administration, Oral; Adult; Antiviral Agents; Benzoates; Carrier Proteins; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Female; Hepatitis C; Humans; Hydrazines; Immunoglobulins, Intravenous; Injections, Subcutaneous; Interferons; Myelodysplastic Syndromes; Placebos; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Ribavirin; Splenectomy; Thrombocytopenia; Thrombopoietin; Time Factors | 2009 |
New options after first-line therapy for chronic immune thrombocytopenic purpura.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Benzoates; Carrier Proteins; Chronic Disease; Drug Resistance; Humans; Hydrazines; Immunologic Factors; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Rituximab; Thrombopoiesis; Thrombopoietin | 2009 |
Orphan disease gains second treatment option.
Topics: Benzoates; Carrier Proteins; Drug Delivery Systems; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Rare Diseases; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin | 2009 |
New therapy options for chronic immune thrombocytopenic purpura: a breath of fresh air. Introduction.
Topics: Benzoates; Chronic Disease; Drug Delivery Systems; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2009 |
Eltrombopag in chronic idiopathic thrombocytopenic purpura.
Topics: Benzoates; Chronic Disease; Double-Blind Method; Hemorrhage; Humans; Hydrazines; Multicenter Studies as Topic; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Quality of Life; Randomized Controlled Trials as Topic | 2009 |
Eltrombopag.
Topics: Benzoates; Clinical Trials as Topic; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2009 |
New drugs 09, part 2.
Topics: Adrenergic Uptake Inhibitors; Angioedemas, Hereditary; Benzoates; Carrier Proteins; Complement C1 Inactivator Proteins; Complement C1 Inhibitor Protein; Drug Approval; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Fluprednisolone; Humans; Huntington Disease; Hydrazines; Keratitis; Nurse's Role; Ophthalmologic Surgical Procedures; Pain, Postoperative; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Pyridines; Receptors, Fc; Recombinant Fusion Proteins; Tetrabenazine; Thrombopoietin; Uveitis | 2009 |
Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.
Topics: Benzoates; Chronic Disease; Drug Approval; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
Update on eltrombopag for ITP.
Topics: Benzoates; Drug Approval; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic | 2009 |
Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Drug Resistance, Neoplasm; Female; Humans; Hydrazines; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Salvage Therapy | 2010 |
Consensus Paper-ICIS Expert Meeting Basel 2009 treatment milestones in immune thrombocytopenia.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Benzoates; Child; Hemorrhage; Humans; Hydrazines; Immunologic Factors; Precision Medicine; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Quality of Life; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Rituximab; Severity of Illness Index; Splenectomy; Switzerland; Thrombocytopenia; Thrombopoietin | 2010 |
Increasing platelets without transfusion: is it time to introduce novel thrombopoietic agents in neonatal care?
Topics: Adult; Age Factors; Apoptosis; Benzoates; Brain; Dose-Response Relationship, Drug; Drug Approval; Humans; Hydrazines; Infant, Newborn; Neurons; Patient Selection; Platelet Transfusion; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia, Neonatal Alloimmune; Thrombopoiesis; Thrombopoietin; United States; United States Food and Drug Administration | 2010 |
Eltrombopag. Idiopathic thrombocytopenic purpura after treatment failure: romiplostim is a better option.
Topics: Benzoates; Hemorrhage; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Treatment Failure | 2010 |
[Diagnosis and therapy of autoimmune thrombocytopenia. Recommendations of a joint Expert Group of DGHO, DGTI, DTH].
Topics: Adrenal Cortex Hormones; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Autoantibodies; Benzoates; Blood Coagulation Tests; Blood Platelets; Blood Transfusion; Child; Cross-Sectional Studies; Diagnosis, Differential; Evidence-Based Medicine; Germany; Hemorrhage; Hospitalization; Humans; Hydrazines; Immunization, Passive; Immunosuppressive Agents; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Recurrence; Rituximab; Splenectomy; Thrombopoietin | 2010 |
Acute renal failure in a patient with antiphospholipid syndrome and immune thrombocytopenic purpura treated with eltrombopag.
Topics: Acute Kidney Injury; Antiphospholipid Syndrome; Benzoates; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2010 |
Sustaining platelet counts in chronic ITP.
Topics: Benzoates; Chronic Disease; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2011 |
Population PK/PD modeling of eltrombopag in healthy volunteers and patients with immune thrombocytopenic purpura and optimization of response-guided dosing.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Asian People; Benzoates; Case-Control Studies; Computer Simulation; Dose-Response Relationship, Drug; Female; Humans; Hydrazines; Male; Middle Aged; Models, Biological; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Young Adult | 2011 |
[New treatment options for primary immune thrombocytopenia].
Topics: Antibodies, Monoclonal, Murine-Derived; Benzoates; Dexamethasone; Glucocorticoids; Humans; Hydrazines; Immunoglobulins, Intravenous; Immunosuppressive Agents; Prednisolone; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Splenectomy; Thrombopoietin | 2011 |
What is publication? The case of eltrombopag.
Topics: Benzoates; Editorial Policies; Humans; Hydrazines; Publishing; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Splenectomy; Thrombopoietin | 2011 |
Infection-related transient loss of response and other early side effects in chronic ITP during treatment with thrombopoietin mimetics.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chronic Disease; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Activation; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Treatment Outcome | 2011 |
Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Blood Platelets; Case-Control Studies; Child; Child, Preschool; Female; Humans; Hydrazines; Immunoglobulins, Intravenous; Infant; Isoantibodies; Male; Middle Aged; Platelet Count; Prognosis; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, IgG; Retrospective Studies; Rh-Hr Blood-Group System; Rho(D) Immune Globulin; Thrombocytosis; Thrombopoiesis; Young Adult | 2011 |
Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent.
Topics: Animals; Benzoates; Blood Platelets; Cell Line; Dose-Response Relationship, Drug; Hepatocytes; Humans; Hydrazines; Injections, Intravenous; Intracellular Signaling Peptides and Proteins; Liver; Liver-Specific Organic Anion Transporter 1; Male; Membrane Proteins; Mice; Mice, Knockout; Organic Anion Transporters; Organic Cation Transporter 1; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, Thrombopoietin; Tissue Distribution | 2011 |
The stingy bone marrow and the wasteful peripheral blood: a tale of two ITPs.
Topics: Animals; Benzoates; Blood Platelets; Bone Marrow; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Thrombopoiesis | 2011 |
Eltrombopag for chronic immune thrombocytopenia.
Topics: Asia; Benzoates; Chronic Disease; Humans; Hydrazines; Multicenter Studies as Topic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Thrombopoietin | 2011 |
Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents.
Topics: Adult; Benzoates; Bone Marrow; Combined Modality Therapy; Cytokines; Female; Hepatocyte Growth Factor; Humans; Hydrazines; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Peptide Fragments; Primary Myelofibrosis; Procollagen; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Reticulin; Splenectomy; Thrombopoietin | 2011 |
Thrombopoietin-receptor agonists in haematological disorders: the Danish experience.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Benzoates; Blood Platelets; Celiac Disease; Denmark; Female; HIV Infections; Humans; Hydrazines; Leukemia, Lymphocytic, Chronic, B-Cell; Lupus Erythematosus, Systemic; Male; Middle Aged; Off-Label Use; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Recurrence; Retrospective Studies; Thrombocytopenia; Thrombopoietin | 2012 |
[Guidelines for diagnosis, treatment and monitoring of primary immune thrombocytopenia].
Topics: Aged; Benzoates; Child; Female; Glucocorticoids; Humans; Hydrazines; Immunoglobulins, Intravenous; Immunologic Factors; Pregnancy; Pregnancy Complications, Hematologic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Quality of Life; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Splenectomy; Thrombopoietin | 2012 |
In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Blood Platelets; Case-Control Studies; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Flow Cytometry; Humans; Hydrazines; Male; Middle Aged; P-Selectin; Peptide Fragments; Platelet Activation; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic | 2012 |
Thrombopoietin: too much or too little.
Topics: Benzoates; Blood Platelets; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Secondary Prevention; Thrombopoietin | 2012 |
Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
Topics: Aged, 80 and over; Benzoates; Dose-Response Relationship, Drug; Drug Resistance; Female; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Treatment Outcome | 2012 |
Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists.
Topics: Benzoates; Blood Coagulation; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Fibrin Fibrinogen Degradation Products; Fibrinolysis; Hemorrhage; Humans; Hydrazines; Platelet Count; Pulmonary Embolism; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Thrombophilia; Thrombopoietin; Venous Thrombosis | 2012 |
Thrombopoietin receptor agonists in the treatment of immune thrombocytopenia: a clinician's perspective.
Topics: Benzoates; Clinical Trials as Topic; Hemorrhage; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin | 2012 |
Platelet count or bleeding as the outcome in ITP trials?
Topics: Benzoates; Clinical Trials as Topic; Hemorrhage; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin | 2012 |
TPO-receptor agonists in ITP: a clinician's navigation between Scylla and Charybdis.
Topics: Benzoates; Clinical Trials as Topic; Hemorrhage; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin | 2012 |
Prolonged remission from eltrombopag in chronic refractory idiopathic thrombocytopenic purpura.
Topics: Benzoates; Chronic Disease; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Remission Induction; Treatment Outcome | 2012 |
Platelet response as the basis for approval in chronic immune (idiopathic) thrombocytopenic purpura (ITP): a regulatory perspective.
Topics: Benzoates; Clinical Trials as Topic; Hemorrhage; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin | 2012 |
Severe cutaneous toxicity related to Eltrombopag.
Topics: Aged; Aged, 80 and over; Benzoates; Female; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Skin Diseases | 2013 |
The beta 1 tubulin R307H single nucleotide polymorphism is associated with treatment failures in immune thrombocytopenia (ITP).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Antibodies, Monoclonal, Murine-Derived; Benzoates; Biomarkers; Child; Child, Preschool; Female; Gene Frequency; Genotype; Humans; Hydrazines; Immunologic Factors; Infant; Male; Middle Aged; Phenotype; Platelet Count; Polymorphism, Single Nucleotide; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Rituximab; Thiazoles; Thiophenes; Thrombopoiesis; Thrombopoietin; Treatment Failure; Tubulin | 2013 |
Successful treatment of eltrombopag-resistant refractory immune thrombocytopenia with romiplostim.
Topics: Benzoates; Drug Resistance; Humans; Hydrazines; Immunoglobulins, Intravenous; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin | 2013 |
Extensive cerebral venous sinus thrombosis following a dose increase in eltrombopag in a patient with idiopathic thrombocytopenic purpura.
Topics: Anticoagulants; Benzoates; Female; Humans; Hydrazines; Magnetic Resonance Imaging; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Sinus Thrombosis, Intracranial; Treatment Outcome | 2014 |
Cardiac and pulmonary thrombosis during multidrug treatment in an idiopathic thrombocytopenic purpura patient.
Topics: Adult; Benzoates; Danazol; Female; Humans; Hydrazines; Immunoglobulins, Intravenous; Methylprednisolone; Pulmonary Embolism; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Venous Thrombosis; Vincristine | 2014 |
Profound thrombocytopenia in patient with ITP treated with chemotherapy for breast cancer and subsequent remission after romiplostim.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzoates; Bone Marrow; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Resistance; Female; Humans; Hydrazines; Mastectomy, Segmental; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Estrogen; Receptors, Fc; Recombinant Fusion Proteins; Remission Induction; Splenectomy; Taxoids; Thrombocytopenia; Thrombopoietin | 2013 |
A comment on Boyers et al.: "eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal".
Topics: Benzoates; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Technology Assessment, Biomedical | 2013 |
The authors' reply to Allen et al.: "A Comment on Boyers et al.: 'eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal'".
Topics: Benzoates; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Technology Assessment, Biomedical | 2013 |
[Eltrombopag increases thrombocyte count and reduces the bleeding risk].
Topics: Benzoates; Hemorrhage; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2007 |
Immune thrombocytopenic purpura--from agony to agonist.
Topics: Benzoates; Hepatitis C; History, 20th Century; Humans; Hydrazines; Liver Cirrhosis; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2007 |
Eltrombopag in thrombocytopenia.
Topics: Adrenal Cortex Hormones; Benzoates; Danazol; Drug Therapy, Combination; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2008 |